Pharmaceutical combinations of amino-pyrrolopyrimidinone compounds and methods of use
The combination therapy of nemtabrutinib and veneclax addresses the limited efficacy of existing BTK inhibitors in the treatment of CLL by enhancing the inhibition of downstream BTK targets, thereby achieving highly effective disease remission and clearance of minimal residual disease.
Patent Information
- Application Number
- CN202380031025.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-29
- Filing Date
- 2023-03-27
- Publication Date
- 2024-11-12
AI Technical Summary
Existing BTK inhibitors, such as ibrutinib, have only achieved complete response in a portion of patients with chronic lymphocytic leukemia (CLL), and long-term use increases dependence on B-cell lymphoma 2 (BCL2). Complete remission is also difficult to achieve with BCL2 inhibitors alone, and the efficacy of existing combination therapies is limited.
The combination therapy of nemtabrutinib and the BCL2 inhibitor veneclax was used. Nemtabrutinib is a reversible inhibitor with a stronger inhibitory effect on downstream targets of BTK. When used in combination with veneclax, it enhances the therapeutic effect on BTK-mediated diseases.
The combination therapy of nemtabrutinib and veneclax significantly improved the treatment efficacy for CLL and other BTK-mediated diseases, achieving a complete remission rate of up to 96% and a minimal residual disease (uMRD) clearance of 69%.
Smart Images

Figure CN118946359A_ABST
Abstract
Description
Background Art
[0001] BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B cell development and mature B cell activation and survival. Downstream of multiple receptors (e.g., growth factors, B cell antigens, chemokines, and innate immune receptors), BTK initiates a variety of cellular processes, including cell proliferation, survival, differentiation, motility, angiogenesis, cytokine production, and antigen presentation.
[0002] BTK-deficient mouse models show the role of BTK in allergic and / or autoimmune and / or inflammatory diseases. For example, BTK deficiency in a standard mouse preclinical model of systemic lupus erythematosus (SLE) has been shown to result in a significant improvement in disease progression. In addition, BTK-deficient mice are resistant to developing collagen-induced arthritis and are less susceptible to staphylococcal-induced arthritis. Due to the role of BTK in B cell activation, BTK inhibitors can also be used as inhibitors of B cell-mediated pathogenic activity (such as autoantibody production). BTK expression in osteoclasts, mast cells and monocytes has been shown to be important for the function of these cells. For example, impaired IgE-mediated mast cell activation and reduced TNF-α production by activated monocytes are associated with BTK deficiency in mice and humans. Therefore, BTK inhibition can be used to treat allergic and / or autoimmune and / or inflammatory diseases, such as: SLE, rheumatoid arthritis, polyangiitis, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis, multiple sclerosis and asthma.
[0003] BTK's role in apoptosis demonstrates the role of inhibiting BTK activity in the treatment of cancer, B-cell lymphoma, leukemia, and other hematological malignancies. In addition, given BTK's role in osteoclast function, inhibition of BTK activity could be used to treat bone diseases such as osteoporosis.
[0004] Many B cell receptor (BCR) signaling antagonists (particularly BTK inhibitors) have shown clinical efficacy in the treatment of chronic lymphocytic leukemia (CLL). Although the treatment is effective, BTK inhibition alone is not enough to eliminate the disease. Only a small number of patients treated with BTK inhibitor (BTKi) ibrutinib achieve complete response, and rarely reach undetectable minimal residual disease (uMRD) (Ahn ie, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018; 131 (21): 2357-66.). Previous studies have shown that long-term BTK inhibition increases dependence on B cell lymphoma 2 (BCL2), an anti-apoptotic protein highly expressed in CLL (Deng J et al., Leukemia. 2017; 31 (10): 2075-84). In a phase 1 clinical trial, the total response rate of patients with relapsed / refractory (R / R) CLL treated with the BCL2 inhibitor venetoclax as a monotherapy was 79%; however, only 5% of patients had uMRD in their bone marrow (Roberts AW et al., N Engl J Med. 2016; 374(4): 311-22). The results of a phase 2 clinical trial of ibrutinib and venetoclax as a first-line treatment showed that after 18 cycles of combined treatment, 96% of patients achieved complete remission and 69% of patients developed bone marrow uMRD, demonstrating the clinical efficacy of the combined treatment (Jain N et al., N Engl J Med. 2019; 380(22): 2095-103).
[0005] The compound nemtabrutinib (also known as MK1026 and ARQ 531) of the present invention is an effective, reversible BTK inhibitor that has a stronger inhibitory effect on BTK downstream targets than ibrutinib and is also effective for R / R disease (Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA et al. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery. 2018; 8(10): 1300-15). The combination of nemtabrutinib with other therapeutic agents (e.g., BCL2 inhibitors) is particularly meaningful for providing treatment for BTK-mediated diseases / disorders. One of the combination therapies is nemtabrutinib combined with venetoclax for the treatment of relapsed / refractory CLL / SLL patients who have previously received at least one therapy. Summary of the invention
[0006] The first aspect of the present application relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I):
[0007]
[0008] or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof, for treating a BTK-mediated disease or condition. As used herein, the expression "compound of formula (I)", "compound (I)" or nemtabrutinib refers to the same compound and can be used interchangeably. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1A Depicted are graphs comparing data for cells treated with venetoclax, compound 1, ibrutinib, and the combination.
[0010] Figure 1B Representative immunoblots are depicted.
[0011] Figure 1C-1E Figures depicting data comparing various proteins of cells treated with venetoclax, Compound 1, ibrutinib, and the combination ( Figure 1C For pBTK, Figure 1D For pERK, Figure 1E for MCL-1).
[0012] Figure 1FDepicted are graphs showing data for cells co-cultured with NK Tert stromal cells, BH3 profiling using BIM, BAD, MS-1 and Y4ek peptides.
[0013] Figure 2A Representative study design for mice treated with vehicle, venetoclax, nemtarutinib, ibrutinib, venetoclax and nemtarutinib, or venetoclax and ibrutinib.
[0014] Figure 2B Depicted are graphs showing survival data for mice treated with vehicle, venetoclax, nemtarutinib, ibrutinib, venetoclax and nemtarutinib, or venetoclax and ibrutinib.
[0015] Figure 2C Depicted are graphs showing the probability of survival for treatment with vehicle, venetoclax, nemtarutinib, ibrutinib, venetoclax and nemtarutinib, or venetoclax and ibrutinib. DETAILED DESCRIPTION
[0016] The first aspect of the present application relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I):
[0017]
[0018] or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof, for treating a BTK-mediated disease or condition.
[0019] Another aspect of the present application relates to a method for treating a BTK-mediated disease or condition in a subject in need thereof, the method comprising co-administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof. Another aspect of the present invention is a method in which a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered simultaneously or co-administered with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof. Another aspect of the present invention is a method in which a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered daily with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof.
[0020] Another aspect of the present application relates to the use of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one second agent or a pharmaceutically acceptable salt thereof in the treatment of a BTK-mediated disease or condition.
[0021] Another aspect of the present application relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in combination therapy with at least one second agent or a pharmaceutically acceptable salt thereof for treating a BTK-mediated disease or condition.
[0022] Another aspect of the present application relates to a method for treating cancer (e.g., hematological cancer, including B-cell lymphoma or non-Hodgkin's lymphoma), wherein a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered together with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof.
[0023] Another aspect of the present application relates to a method for treating cancer, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL). Another aspect of the present application relates to a method for treating chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
[0024] Another aspect of the present application relates to a method of regulating (eg, inhibiting) or modulating (eg, inhibiting) BTK by administering a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one second agent or a pharmaceutically acceptable salt thereof.
[0025] Another aspect of the present application relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating a BTK-mediated disease or condition.
[0026] Another aspect of the present application relates to the use of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one second agent or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a BTK-mediated disease or condition.
[0027] Another aspect of the present application relates to a pharmaceutical composition of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one second agent, wherein the second agent is selected from venetoclax, BI-97C1, sabutoclax, navitoclax, obatoclax, 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylthiobutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide (ABT-737), N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide (TW-37), APG-1252, APG-2575 or S55746. Another aspect is a composition of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with venetoclax, or a pharmaceutically acceptable salt thereof.
[0028] On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax contains about 30 mg to about 80 mg of the compound of formula (I) or its pharmaceutically acceptable salt. On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax contains about 45 mg of the compound of formula (I) or its pharmaceutically acceptable salt. On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax contains about 65 mg of the compound of formula (I) or its pharmaceutically acceptable salt. On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax contains about 80 mg of the compound of formula (I) or its pharmaceutically acceptable salt.
[0029] On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax or its pharmaceutically acceptable salt comprises about 30mg to about 80mg of the compound of formula (I) or its pharmaceutically acceptable salt, and about 400mg of Venetoclax or its pharmaceutically acceptable salt. On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax comprises about 45mg of the compound of formula (I) and about 400mg of Venetoclax. On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax or its pharmaceutically acceptable salt comprises about 65mg of the compound of formula (I) and about 400mg of Venetoclax. On the other hand, the pharmaceutical composition of the combination of a compound of formula (I) or its pharmaceutically acceptable salt and Venetoclax or its pharmaceutically acceptable salt comprises about 80mg of the compound of formula (I) or its pharmaceutically acceptable salt, and about 400mg of Venetoclax or its pharmaceutically acceptable salt.
[0030] Another aspect of the present application relates to a method of treating a BTK-mediated disorder in a subject in need thereof, wherein the method comprises co-administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
[0031]
[0032] Or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof. In another aspect, the method comprises administering a compound of formula (I) after administering the second agent. In another aspect, the BTK-mediated condition treated is a cancer selected from CLL, SLL or MLL. In another aspect, the method comprises administering a second agent selected from venetoclax, BI-97C1, sabutoclax, navitoclax, obatoclax, 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylthiobutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide (ABT-737), N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide (TW-37), APG-1252, APG-2575 or S55746. Another aspect is a method in which a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered together with venetoclax or a pharmaceutically acceptable salt thereof. Another aspect is a method in which a compound of formula (I) or a pharmaceutically acceptable salt thereof is co-administered with venetoclax or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered after administration of venetoclax or a pharmaceutically acceptable salt thereof. In another aspect, the compound of formula (I) is administered at least 10 hours after administration of venetoclax.
[0033] Another aspect of the present application relates to a method for treating a BTK-mediated condition in a subject in need thereof, wherein the BTK-mediated condition is a cancer selected from CLL, SLL or MLL, and the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof in combination. Another aspect of the present application is a method for treating a BTK-mediated condition, wherein the second agent is venetoclax or a pharmaceutically acceptable salt thereof. Another aspect of the method comprises administering about 30 mg to about 80 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof after administering about 20 to about 400 mg of venetoclax or a pharmaceutically acceptable salt thereof. On the other hand, the method comprises administering about 45 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof after administering about 400 mg of venetoclax or a pharmaceutically acceptable salt thereof. On the other hand, the method comprises administering about 65 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof after administering about 400 mg of venetoclax or a pharmaceutically acceptable salt thereof. In another aspect, the method comprises administering about 80 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, after administering about 400 mg of venetoclax or a pharmaceutically acceptable salt thereof.
[0034] The present application relates to a drug combination or combination therapy capable of regulating the activity of Bruton's tyrosine kinase (BTK). The present application is characterized in that a method for treating a disease or condition in which BTK plays a role is provided by administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a second agent (as described herein) to a patient in need thereof. The method of the present application can be used to treat a variety of BTK-mediated diseases and conditions by inhibiting the activity of BTK kinase. Inhibiting BTK provides treatment, prevention or improvement of diseases, including but not limited to immune diseases, cancer, cardiovascular diseases, viral infections, inflammation, metabolic / endocrine dysfunction and nervous system diseases.
[0035] The compound of formula (I) or a pharmaceutically acceptable salt thereof has the following structure:
[0036]
[0037] Also known as nemtabrutinib, MK-1026, formerly known as ARQ531, is a reversible non-covalent adenosine triphosphate (ATP) competitive inhibitor of Bruton's tyrosine kinase (BTK), intended to target wild-type and BTK-C481S mutants. The method for preparing the compound is described in U.S. Patent No. 9,630,968, which is incorporated herein by reference in its entirety. The present invention includes compounds of formula (I) described in the '968 patent and salts thereof. Compared with another BTK inhibitor, ibrutinib, compound (I) (nemtarutinib) has a stronger inhibitory effect on the downstream targets of BTK (Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA et al. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery. 2018; 8 (10): 1300-15).
[0038] This application provides the medical community with a new pharmacological strategy for treating diseases and conditions associated with BTK kinase. The results of a Phase 2 clinical trial of ibrutinib and venetoclax as a first-line treatment showed that after 18 cycles of combined treatment, 96% of patients achieved complete remission and 69% of patients developed bone marrow uMRD, demonstrating the clinical efficacy of the combined treatment (Jain N et al., N Engl J Med. 2019; 380(22): 2095-103).
[0039] The present application provides a drug combination or combination therapy using a compound of formula I or a pharmaceutically acceptable salt thereof, which has additive or synergistic effects and safety relative to known treatments. One aspect of the present invention relates to a method for treating a BTK-mediated disease or condition in a subject in need thereof, the method comprising co-administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof, wherein the BTK-mediated disease state or condition is cancer, and the second agent is venetoclax or a pharmaceutically acceptable salt thereof.
[0040] The details of the present application are shown in the attached description below. Although methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present application, illustrative methods and materials are now described. Other features, objects and advantages of the present application are apparent from the specification and claims. Unless the context clearly provides otherwise, in the specification and the appended claims, singular forms also include plural forms. Unless otherwise defined, all technical and scientific terms used in the present application have the same meanings as those of ordinary skill in the art to which the present application belongs. All patents and publications cited in this specification are incorporated herein by reference in their entirety.
[0041] definition
[0042] The article "a / a" is used in this application to refer to one / a kind or more / a kind (ie, at least one / a kind) of the grammatical object of the article. For example, "an element" refers to one element or more elements.
[0043] As used in this application, the term "and / or" means "and" or "or" unless stated otherwise.
[0044] The present application also includes a pharmaceutical composition comprising an effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier. The term "carrier" as used in the present application includes carriers, excipients and diluents, and refers to materials, compositions or carriers involved in transporting or transporting a drug from one organ or part of the body to another organ or part of the body, such as liquid or solid fillers, diluents, excipients, solvents or packaging materials.
[0045] The compounds of formula (I) may be in the form of salts, esters, prodrugs, solvates, tautomers, isotopes, and the like, which are also within the scope of the present application and are taught in U.S. Pat. No. 9,630,968, which is incorporated herein by reference.
[0046] In the present specification, for convenience, the structural formula of the compound represents a certain isomer in some cases, but the present application includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, etc., as shown in U.S. Patent No. 9,630,968, which is incorporated herein by reference.
[0047] Compounds of Formula (I) may be more effective than one or more known BTK inhibitors in inhibiting the activity of BTK containing one or more mutations described herein (e.g., C481S), including but not limited to ibrutinib, GDC-0834, RN486, CGI-560, CGI-1746, HM-71224, CC-292, ONO-4059, CNX-774, LFM-A13, GDC-0853, LOU684, PRN1008, acalabrutinib, zanubrutinib and / or PRN2246. For example, the compound is at least about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or about 100-fold more potent (e.g., as measured by IC ) than ibrutinib, GDC-0834, RN486, CGI-560, CGI-1746, HM-71224, CC-292, ONO-4059, CNX-774, LFM-A13, GDC-0853, LOU684, PRN1008, acalabrutinib, zanubrutinib, and / or PRN2246 in inhibiting the activity of BTK containing one or more mutations described herein. 50 The drug-resistant BTK mutation may include, but is not limited to, a drug-resistant mutation including a C481S mutation.
[0048] The terms "administering" or "administration" as used in this application refer to directly administering a disclosed compound or a pharmaceutically acceptable salt or composition of a disclosed compound to a subject, or administering a prodrug, derivative or analog or composition of the compound or a pharmaceutically acceptable salt of the compound to a subject, which can form an equivalent amount of active compound in the subject's body.
[0049] "Patient" or "subject" refers to a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey.
[0050] An "effective amount" or "therapeutically effective amount" when used in connection with a compound or pharmaceutical composition is an amount effective to treat or prevent a disease in a subject as described herein.
[0051] With respect to a subject, the term "treatment" refers to ameliorating at least one symptom of a disease in a subject. Treatment includes curing, ameliorating or at least partially alleviating a disease.
[0052] The compounds of the present application or their pharmaceutically acceptable salts may also be used in combination with a second therapeutic agent to prevent a disease, condition or disorder. As used herein, "prevent" or "preventing" refers to reducing or eliminating the onset of symptoms or complications of a disease, condition or disorder.
[0053] Unless otherwise indicated, the term "disorder" used in this application refers to a disease, condition or illness, and can be used interchangeably with a disease, condition or illness. As used herein, the term "BTK-mediated" disease or condition refers to any disease or other harmful condition in which BTK or its mutants are known to play a role. Therefore, another embodiment of the present application is directed to treating or reducing the severity of one or more diseases in which BTK or its mutants are known to play a role. Specifically, the present application is directed to a method for treating or reducing the severity of a disease or condition selected from a proliferative disease or an autoimmune disease, wherein the method comprises administering a compound of formula (I) of the present application or a pharmaceutically acceptable salt or composition thereof to a patient in need thereof.
[0054] As used herein, the term "cell proliferative disorder" refers to a condition (which may or may not be cancerous) in which the unregulated or abnormal growth of cells or both may lead to an undesirable condition or disease development. Exemplary cell proliferative disorders of the present application include a variety of conditions in which cell division is unregulated. Exemplary cell proliferative disorders include, but are not limited to, tumors, benign tumors, malignant tumors, precancerous diseases, tumors in situ, encapsulated tumors, metastatic tumors, liquid tumors, solid tumors, immune tumors, blood tumors, cancers, epithelial cancers, leukemias, lymphomas, sarcomas, and rapidly dividing cells. The term "rapidly dividing cell" as used herein is defined as any cell that divides at a rate that exceeds or is greater than the expected or observed rate of adjacent or abutting cells in the same tissue.
[0055] Cell proliferative disorders include precancerous or precancer conditions. Cell proliferative disorders include cancer. Preferably, the methods provided herein are used to treat or alleviate cancer symptoms. The term "cancer" includes solid tumors as well as hematological tumors and / or malignancies. "Precancerous cells" or "precancerous cells" refer to cells that exhibit a cell proliferative disorder that is a precancerous or precancerous condition. "Cancer cells" or "cancerous cells" refer to cells that exhibit a cell proliferative disorder that is a cancer. Any repeatable measurement method can be used to identify cancer cells or precancerous cells. Cancer cells or precancerous cells can be identified by tissue typing or grading of tissue samples (e.g., biopsy samples). Cancer cells or precancerous cells can be identified by using appropriate molecular markers.
[0056] Exemplary non-cancerous BTK-mediated diseases or conditions are described in U.S. Pat. No. 9,630,968, which is incorporated herein by reference.
[0057] Process for preparing compounds of formula I
[0058] Compounds of formula I may be prepared by a variety of methods, including standard chemical methods. Compounds of formula (I) may be prepared by methods known in the art of organic synthesis, such as described in US Pat. No. 9,630,968, which is incorporated herein by reference.
[0059] The compounds described herein can be prepared from commercially available starting materials or synthesized using known organic, inorganic and / or enzymatic methods. The compounds of the present application can be prepared in a variety of ways well known to those skilled in the art of organic synthesis.
[0060] How to use the compound
[0061] Aspects of the present application relate to methods for treating, preventing, inhibiting or eliminating diseases or conditions associated with BTK regulation (e.g., BTK inhibition). The method includes administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a combination of a compound of formula (I) and a second agent described herein to a patient who needs to treat a disease or condition associated with BTK regulation. In one embodiment, BTK-mediated conditions are selected from immune diseases, cancer, cardiovascular diseases, viral infections, inflammation, metabolic / endocrine dysfunction, and nervous system diseases.
[0062] In embodiments, the BTK is a mutant BTK (eg, a BTK C481S mutant).
[0063] One aspect of the invention relates to a method comprising administering at least one second agent selected from the group consisting of an anti-inflammatory agent, an immunomodulatory agent, a chemotherapeutic agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an antiviral agent, an agent for treating blood disorders, an agent for treating diabetes, and an agent for treating immunodeficiency disease.
[0064] Another aspect of the present application relates to a method of regulating BTK, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a combination of a compound of formula (I) and a second agent described herein. In one embodiment, regulating BTK is inhibiting BTK.
[0065] Another aspect of the present application relates to a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a second agent as described herein for use in a method for treating a BTK-mediated disorder. In one embodiment, the disease or disorder is selected from immune disease, cancer, cardiovascular disease, viral infection, inflammation, metabolic / endocrine dysfunction, and nervous system disease.
[0066] In an embodiment, the method described herein comprises administering at least one second agent selected from an anti-inflammatory agent, an immunomodulatory agent, a chemotherapeutic agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an antiviral agent, an agent for treating blood disease, an agent for treating diabetes, and an agent for treating an immunodeficiency disease.
[0067] In some embodiments, BTK is wild-type BTK. In other embodiments, BTK is a mutant BTK (e.g., BTK C481S mutant).
[0068] In another aspect, the present application relates to a composition of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a second agent as described herein for use in a method of treating a BTK-mediated disease.
[0069] Another aspect of the present application relates to a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a second agent as described herein for use in a method of treating, preventing, inhibiting or eliminating a cell proliferative disease. In one embodiment, the cell proliferative disease is cancer.
[0070] In another aspect, the present application relates to a pharmaceutical composition of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and the second agent described herein for use in a method of treating, preventing, inhibiting or eliminating a cell proliferative disease. In one embodiment, the cell proliferative disease is cancer.
[0071] In some embodiments of the methods and uses described herein, the cancer is selected from breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, genitourinary tract cancer, esophageal cancer, laryngeal cancer, glioblastoma, neuroblastoma, gastric cancer, skin cancer, keratoacanthoma, lung cancer, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer (NSCLC), small cell carcinoma, lung adenocarcinoma, bone cancer, colon cancer, adenoma, pancreatic cancer, adenocarcinoma, thyroid cancer, follicular carcinoma, undifferentiated Carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder cancer, liver cancer and bile duct cancer, kidney cancer, pancreatic cancer, bone marrow disease, lymphoma, hairy cell cancer, oral cancer, nasopharyngeal cancer, pharyngeal cancer, lip cancer, tongue cancer, mouth cancer, small intestine cancer, colorectal cancer, large intestine cancer, rectal cancer, brain cancer and central nervous system cancer, Hodgkin lymphoma, bronchial cancer, thyroid cancer, liver cancer and intrahepatic bile duct cancer, hepatocellular carcinoma, stomach cancer, glioma / glioblastoma, intrauterine cancer Membranous cancer, melanoma, cancer of the kidney and renal pelvis, cancer of the urinary bladder, cancer of the uterine corpus, cancer of the cervix, multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia, lymphocytic leukemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma (MCL), CNS lymphoma (primary and secondary), marginal zone lymphoma, myeloid leukemia, childhood sarcoma, childhood brain tumor, cancer of the oral cavity and pharynx, non-Hodgkin lymphoma, melanoma, villous colon adenoma, Richter's transformation, and Waldenstrom's macroglobulinemia. The terms "CLL" and "SLL" refer to the same disease in different anatomical locations. CLL and SLL have the same treatment paradigm and expected clinical outcomes. CLL is sometimes used as a term that encompasses both CLL and SLL.
[0072] In any embodiment of the present application, the cancer can be any cancer in any organ, for example, a cancer selected from glioma, thyroid cancer, breast cancer, small cell lung cancer, non-small cell cancer, gastric cancer, colon cancer, gastrointestinal stromal cancer, pancreatic cancer, bile duct cancer, CNS cancer, ovarian cancer, endometrial cancer, prostate cancer, renal cancer, anaplastic large cell lymphoma, leukemia, multiple myeloma, mesothelioma and melanoma, and combinations thereof.
[0073] In any embodiment of the invention, the cancer is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL). In any embodiment, the cancer is chronic lymphocytic leukemia (CLL).
[0074] In some embodiments of the methods and uses described herein, the disease or disorder is an immune disease. In one embodiment, the immune disease is rheumatoid arthritis.
[0075] In some embodiments of the methods and uses described herein, the disease or disorder is systemic and local inflammation, arthritis, inflammation associated with immunosuppression, organ transplant rejection, allergy, ulcerative colitis, Crohn's disease, dermatitis, asthma, systemic lupus erythematosus, Sjögren's syndrome, multiple sclerosis, scleroderma / systemic sclerosis, idiopathic thrombocytopenic purpura (ITP), anti-neutrophil cytoplasmic antibodies (ANCA) vasculitis, chronic obstructive pulmonary disease (COPD), psoriasis.
[0076] In one embodiment, the method of treating a disease or condition associated with BTK modulation (including immune diseases, cancer, cardiovascular diseases, viral infections, inflammation, metabolic / endocrine dysfunction, and neurological diseases) comprises administering to a patient suffering from at least one of said diseases or conditions a compound of formula (I) and at least one second agent.
[0077] The compound of formula (I) can be administered in a therapeutically effective amount in a combination therapy with one or more therapeutic agents (drug combination) or a program (e.g., non-drug therapy). For example, a synergistic effect can be produced with other anti-proliferative, anti-cancer, immunomodulatory or anti-inflammatory substances. In some embodiments, the compound of formula (I) is administered in combination with at least one second agent, the second agent being selected from anti-inflammatory agents, immunomodulators, chemotherapeutic agents, neurotrophic factors, agents for treating cardiovascular diseases, agents for treating liver diseases, antiviral agents, agents for treating blood diseases, agents for treating diabetes, and agents for treating immunodeficiency diseases. When the compound of formula (I) is co-administered with other therapies, the dosage of the co-administered compound will naturally change according to the type of the combined drug used, the specific drug used, the disease treated, etc.
[0078] Combination therapy includes the administration of compound (I) in further combination with at least one second agent (biologically active ingredients, such as but not limited to anti-inflammatory agents, immunomodulators, chemotherapeutic agents, neurotrophic factors, agents for treating cardiovascular disease, agents for treating liver disease, antiviral agents, agents for treating blood diseases, agents for treating diabetes and agents for treating immunodeficiency diseases).
[0079] In one embodiment, the compound of formula (I) is used in combination with at least one second agent, preferably a compound that can enhance the effect of the compound of formula (I). The compound of formula (I) and the second agent can be administered simultaneously (as a single preparation or a separate preparation) or sequentially. In general, combined therapy envisions the administration of two or more drugs during a single cycle or treatment course. In an embodiment of the present invention, the method includes administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof before administering a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof. In an embodiment of the present invention, the co-administration of a compound of formula (I) and a second agent occurs within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours or 24 hours. In an embodiment of the invention, the co-administration of a compound of formula (I) and a second agent occurs within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days. In an embodiment of the invention, the co-administration of a compound of formula (I) and a second agent occurs within 1 week, 2 weeks, 3 weeks, or 4 weeks.
[0080] The second agent may include, but is not limited to, an alkylating agent, an antibiotic, an antibiotic antineoplastic agent, an antimetabolite, an antimetabolite antineoplastic agent, an antidote, an interferon, a polyclonal or monoclonal antibody, a Bcl-2 inhibitor, a BTK inhibitor, an mTOR kinase inhibitor, an immunomodulatory drug (ImiD), a TOPK inhibitor, a sphingosine-1-phosphate receptor agonist, an anti-T cell immunoglobulin, an anti-IL-2 receptor antibody, an amide, an EGFR inhibitor, a HER2 inhibitor, a histone deacetylase inhibitor, a hormone or a hormone analog, a mitotic inhibitor, a kinase inhibitor, a multikinase inhibitor, a serine / threonine kinase inhibitor, a tyrosine kinase inhibitor, a VEGF / VEGFR inhibitor, a taxane or a taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule-targeted drug, an antimicrotubule agent, an antimitotic agent, a mitotic inhibitor, a topoisomerase toxic drug, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), a cytidine analog, a phosphatidylinositol-3 kinase (PI3K) inhibitor, an antibody antagonist of a receptor kinase ligand binding, an anti- Angiogenic therapeutic agent, SH2 / SH3 domain blocker, inositol signaling inhibitor, Ras oncogene inhibitor, anti-tumor agent, anti-proliferative agent, additional therapeutic agent, antiviral agent, antigen or adjuvant, cytotoxic agent, retinoid, chemotherapeutic agent, cell cycle signaling inhibitor, therapeutic agent for pro-apoptotic regimen, PARP inhibitor, agent for immunotherapy regimen, checkpoint inhibitor, PD-1 or PD-L1 inhibitor, anti-PD-L1 antibody, PD-1 antagonist, PD-1 inhibitor, ICO S antibody, OXO40 antibody, TLR agonist, TLR4 agonist, therapeutic agents useful for preventing or treating bacterial and viral infections, therapeutic agents useful for treating TB infection (Mycobacterium tuberculosis) and tularemia (Franciscoides tularensis), therapeutic agents useful for treating Chlamydia, therapeutic agents useful for treating Plasmodium infection, vaccines, immunizing antigens, anti-inflammatory agents, or any chemotherapeutic agent, anti-tumor agent or anti-proliferative agent listed at www.cancer.org / docroot / cdg / cdg_0.asp.
[0081] B-cell lymphoma 2 protein (Bcl-2) is an important regulator of programmed cell death (apoptosis). Bcl-2 inhibitors may include, but are not limited to, venetoclax, BI-97C1, sabutoclax, navitoclax, obaclax, 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylthiobutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide (ABT-737), N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide (TW-37), APG-1252 (Ascentage Pharma), APG-2575 (Ascentage Pharma) or S55746 (Servier). Bcl-2 inhibitors may also include, but are not limited to, other chemical substances, such as antisense RNA, siRNA, peptide-based inhibitors, and antibody inhibitors of Bcl-2. Bcl-2 inhibitors may also include, but are not limited to, inhibitors of other members of the Bcl-2-mediated signal transduction pathway, which may replace or supplement the Bcl-2 inhibitor. In one embodiment of the invention, the second agent is a Bcl-2 inhibitor. In one embodiment of the invention, the second agent is venetoclax.
[0082] Exemplary BTK inhibitors may include, but are not limited to, ibrutinib, ACP-196 (acalabrutinib), BGB-3111 (zanubrutinib), spebrutinib, ONO-4059, HM71224, RN486, 4-(4-((4-((3-acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)-N-methylpicolinamide (CNX-774), N-[3-[4,5-dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxopyrazinyl]-2-methylphenyl]-4-(1,1- 15 / 075,033, the disclosures of which are incorporated herein by reference in their entirety. BTK inhibitors may include, but are not limited to, other chemical substances, such as antisense RNA, siRNA, peptide-based inhibitors, and antibody inhibitors of BTK. In some embodiments, the BTK inhibitor may irreversibly bind to BTK.
[0083] In some embodiments, the BTK inhibitor can bind to a mutated BTK, such as a BTK mutated at C481, such as a C481S mutation. In some embodiments, the BTK inhibitor may include, but is not limited to, inhibitors of other members of the BTK-mediated signal transduction pathway. Inhibitors of other members of the BTK-mediated signal transduction pathway may include, but are not limited to, inhibitors of protein kinase C (PKC) β, such as enzastaurin and sotrastaurin. In some embodiments, the BTK inhibitor is ibrutinib, acalabrutinib, or zanubrutinib.
[0084] Immunomodulatory drugs (IMiDs) can be used to treat a variety of inflammatory and autoimmune diseases. IMiDs can also be used to treat neoplastic diseases, such as hematological tumors, such as multiple myeloma and myelodysplastic syndrome, and certain solid tumors. Exemplary immunomodulatory drugs (IMiDs) may include, but are not limited to, lenalidomide, pomalidomide, thalidomide, lepril, CC-112, and CC-220.
[0085] Mammalian target of rapamycin (mTOR) is a protein kinase that serves as a key regulator of cell growth, proliferation, metabolism and apoptosis. Exemplary mTOR kinase inhibitors may include, but are not limited to, everolimus, rapamycin, [7-(6-amino-3-pyridinyl)-2,3-dihydro-1,4-benzoxazin-4(5H)-yl][3-fluoro-2-methyl-4-(methylsulfonyl)phenyl]-methanone (XL388), N-ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyridinol[ 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide (AZD2014 (AstraZeneca)), (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol (AZD8055), GSK105965, 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (TAK-228 or MLN0128 (Takeda)), temsirolimus, ridaforolimus, PI-103, NVP-BEZ235, WJD008, XL765 , SF-1126, Torin1, PP242, PP30, Ku-0063794, WYE-354, WYE-687, WAY-600, INK128, OSI-027, gedatolisib or PF-05212384 (Pfizer), CC-223 (Celgene), LY3023414 (Lilly), PQR309 (PIQUR Therapeutics), LXI-15029 (LuoxinPharma) and SAR245409 (Sanofi). Exemplary mTOR kinase inhibitors may also include, but are not limited to, other chemical substances, such as antisense RNA, siRNA, peptide-based inhibitors and antibody inhibitors of mTOR. Exemplary mTOR kinase inhibitors may also include, but are not limited to, inhibitors of other members of the mTOR-mediated signal transduction pathway.Inhibitors of other members of the mTOR-mediated signal transduction pathway may include, but are not limited to, inhibitors of phosphatidylinositol 3-kinase (PI3K), such as BTG226, gilead, apitolisib, omipalisib, dactolisib, duvelisib (COPIKTRA), idelalisb (Zydeli), temsirolimus (Torisel), rapamycin, defolimus and AP23573, and inhibitors of Akt (protein kinase B), such as 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; dihydrochloride (MK-2206).
[0086] Exemplary TOPK inhibitors include, but are not limited to, OTS964 ((R)-9-(4-(1-(dimethylamino)propan-2-yl)phenyl)-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one).
[0087] Exemplary sphingosine-1-phosphate receptor agonists may include, but are not limited to, fingolimod and KRP-203.
[0088] Exemplary anti-T cell immunoglobulins may include, but are not limited to, anti-thymocyte globulin
[0089] Exemplary anti-IL-2 receptor antibodies may include, but are not limited to, daclizumab.
[0090] Exemplary amides may include, but are not limited to, CTX.
[0091] Exemplary second agents may also include, but are not limited to, ifosfamide (IFO), doxorubicin (ADM), daunorubicin (DNR), vincristine (VCR), vinblastine (VBL), etoposide (VP16), vermeer (Vumon), carboplatin (CBP) and methotrexate (MTX) cyclosporine A, tacrolimus, sirolimus, everolimus, azathioprine, brequinar, leflunomide, LEA-29Y, anti-CD3 antibodies (e.g., OKT3), aspirin, B7-CD28 blocking molecules (e.g., belatacept, abatacept), CD40-CD154 blocking molecules (anti-CD40 antibodies), acetaminophen, ibuprofen, naproxen, piroxicam and anti-inflammatory steroids (e.g., prednisolone or dexamethasone).
[0092] Alkylating agents are non-phase specific agents and strong electrophiles. Typically, alkylating agents form covalent bonds with DNA via nucleophilic moieties (e.g., phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazole) of the DNA molecule by alkylation. This alkylation destroys nucleic acid function and leads to cell death. Examples of alkylating agents include, but are not limited to, nitrogen mustards, such as cyclophosphamide (e.g., ), melphalan (e.g., ) and chlorambucil (e.g. ); alkyl sulfonates, such as busulfan (e.g., ); nitrosoureas, such as carmustine (eg ); and triazenes, such as dacarbazine (e.g., ).
[0093] Exemplary alkylating agents also include, but are not limited to, busulfan (Busulfex), lomustine (CeeNU), oxaliplatin (Eloxatin), carmustine (Gliadel), ifosfamide (Ifex), bis(chloromethyldiethylamine) (Mustargen), busulfan (Myleran), carboplatin Cisplatin (CDDP, ), temozolomide (Temodar), thiotepa (Thioplex), bendamustine (Treanda), streptozotocin (Zanosar), 5-azacytidine (e.g., VIDAZA), decitabine (e.g., DECOGEN), temozolomide (e.g., TEMODAR and TEMODAL), dactinomycin (also known as actinomycin-D, sold under the trade name COSMEGEN), melphalan (also known as L-PAM, L-mylolysin, and phenylalanine mustard, sold under the trade name ALKERAN), octamide (also known as hexamethylmelamine (HMM), sold under the trade name HEXALEN), carmustine (e.g., BCNU, BiCNU), bendamustine (e.g., TREANDA), carboplatin (e.g., ), lomustine (also known as CCNU, sold under the trade name Cisplatin (also known as CDDP, sold under the trade name and Sold under the trade name and ), dacarbazine (also known as DTIC, DIC, and imidazole carboxamide, sold under the trade name Sold), hexamethylmelamine (also known as hexamethylmelamine (HMM), sold under the trade name sold), ifosfamide (e.g. ), procarbazine (e.g. ), dichloromethyl diethylamine (also known as nitrogen mustard, nitrogen mustard hydrochloride and dichloromethyl diethylamine hydrochloride, known as sold), streptozotocin (e.g. ) and thiotepa (also known as thiophosphoramide, TESPA, and TSPA, and sold under the trade names sell).
[0094] Antibiotic antineoplastic agents are non-phase specific agents that bind to or intercalate into DNA. Typically, this action results in stable DNA complexes or strand breaks, thereby disrupting the normal function of the nucleic acid and causing cell death. Examples of antibiotic antineoplastic agents include, but are not limited to, actinomycins, such as actinomycin (e.g. ), anthracyclines such as daunorubicin (e.g., as a liposomal injectable form Or as an injection ) and doxorubicin (e.g. or ADRIAMYCIN ) and bleomycin (e.g., ). Exemplary anthracyclines include, but are not limited to, daunomycin, doxorubicin, epirubicin, idarubicin, and valrubicin.
[0095] Exemplary antibiotics also include, but are not limited to, doxorubicin (Adriamycin), doxorubicin liposome (Doxil), mitoxantrone (Novantrone), bleomycin (Blenoxane), daunorubicin (Cerubidine), daunorubicin liposome (DaunoXome), actinomycin (Cosmegen), epirubicin (Ellence), idarubicin (Idamycin), plicamycin (Mithracin), mitomycin (Mutamycin), pentostatin (Nipent), valrubicin (Valstar), doxorubicin (e.g. and ), bleomycin (e.g. ), daunorubicin (also known as daunorubicin hydrochloride, daunomycin and daunorubicin hydrochloride, known under the trade name daunorubicin liposomes (daunorubicin citrate liposomes, sold under the trade name DAUNOXOME), mitoxantrone (also known as DHAD, sold under the trade name Sold), epirubicin (such as ELLENCE TM ), Idabistar (e.g. IDAMYCIN ) and mitomycin C (e.g. ).
[0096] Antimetabolite antineoplastic agents are phase-specific agents that act during the S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting the synthesis of purine or pyrimidine bases, thereby limiting DNA synthesis. As a result, the S phase does not proceed and cell death ensues. Examples of antimetabolite antineoplastic agents include, but are not limited to, fluorouracil and its analogs (e.g., 5-fluorodeoxyuridine (floxuridine), 5-fluorodeoxyuridine monophosphate methotrexate), cytarabine (commonly known as Ara-C, ) and their analogs (e.g., azacytidine, 2',2'-difluorodeoxycytidine (gemcitabine)), mercaptopurines (e.g. ) and its analogs (e.g., azathiopurine), thioguanine (e.g. ) and its analogs (e.g., pentostatin, erythrohydroxy-nonyl adenine (EHNA), fludarabine phosphate and cladribine), gemcitabine (e.g. ) and methotrexate.
[0097] Exemplary antimetabolites also include, but are not limited to, fluorouracil (Adrucil), capecitabine (Xeloda), hydroxyurea (Hydrea), mercaptopurine (Purinethol), pemetrexed (Alimta), fludarabine (Fludara), nelarabine (Arranon), cladribine (Cladribine Novaplus), clofarabine (Clolar), cytarabine (Cytosar-U), decitabine (Dacogen), cytarabine liposomal (DepoCyt), hydroxyurea (Droxia), pralatrexate (Folotyn), floxuridine (FUDR), gemcitabine (Gemzar), cladribine (Leustatin), fludarabine (Oforta), methotrexate (MTX, Rheumatrex), methotrexate (Trexall), thioguanine (Tabloid), TS-1 or cytarabine (Tarabine PFS), clabine (2-chlorodeoxyadenosine, sold under the trade name Sold under the trade name Sold), 6-thioguanine (trade name Pemetrexed (sold under the trade name arabinoside (also known as cytosine arabinoside (Ara-C), sold under the trade name cytarabine liposomes (also known as Ara-C liposomes, sold under the trade name DEPOCYT TM Sold under the trade name Sold under the trade names DROXIA TMand MYLOCEL TM Sold under the trade name Sold under the trade name Cladribine (also known as 2-chlorodeoxyadenosine (2-CdA), sold under the trade name LEUSTATIN TM Sold in the United States), methotrexate (also known as methotrexate, methotrexate sodium (MTX), and sold under the trade name and TREXALL TM and pentostatin (sold under the brand name sell).
[0098] Exemplary antidotes include, but are not limited to, amifostine (Ethyol) and mesna (Mesnex).
[0099] Exemplary interferons include, but are not limited to, interferon alpha-2b (Intron A) and interferon alpha-2a (Roferon-A).
[0100] Exemplary polyclonal or monoclonal antibodies include, but are not limited to, trastuzumab (Herceptin), ofatumumab (Arzerra), bevacizumab (Avastin), rituximab (Rituxan), cetuximab (Erbitux), panitumumab (Vectibix), tositumumab / iodine 131 Tositumomab (Bexxar), alemtuzumab (Campath), ibritumomab tiuxetan (Zevalin, In-111, Y-90Zevalin), gemtuzumab (Mylotarg), eculizumab (Soliris), ordenosumab, denosumab, and anti-CD20 antibodies (e.g., rituximab (Rituxan), obinutuzumab (Gazyva), ofatumumab (Arzerra), and ublituximab).
[0101] Exemplary EGFR inhibitors include, but are not limited to, gefitinib (Iressa), lapatinib (Tykerb), cetuximab (Erbitux), erlotinib (Tarceva), panitumumab (Vectibix), PKI-166, canertinib (CI-1033), matuzumab (Emd7200), and EKB-569.
[0102] Exemplary HER2 inhibitors include, but are not limited to, trastuzumab (Herceptin); lapatinib (Tykerb), and AC-480.
[0103] Exemplary histone deacetylase inhibitors include, but are not limited to, vorinostat (Zolinza).
[0104] Hormones and hormone analogs are useful compounds for the treatment of cancer where there is a relationship between the hormone and the growth and / or lack of growth of the cancer. Examples of hormones and hormone analogs used in cancer treatment include, but are not limited to, adrenocortical steroids, such as prednisone and prednisolone; aminoglutamine and other aromatase inhibitors, such as, but not limited to, anastrozole, letrozole, vorozole, and exemestane; progestins, such as megestrol acetate; estrogens and antiestrogens, such as fulvestrant, flutamide, nilutamide, bicalutamide, cyproterone acetate, and 5-reductases, such as finasteride and dutasteride; antiestrogens, such as tamoxifen, toremifene, raloxifene, droloxifene, idoxifene, and selective estrogen receptor modulators (SERMS), such as those described in U.S. Pat. Nos. 5,681,835, 5,877,219, and 6,207,716; and gonadotropin-releasing hormone (GnRH) and its analogs; and LHRH agonists and antagonists, such as goserelin acetate and leuprolide.
[0105] Exemplary aromatase inhibitors include, but are not limited to, aminoglutamine, testolactone (Teslac), anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin), vorozole (Rivizor), formestane (Lentaron), fadrozole (Afema), 4-androstene-3,6,17-trione (6-OXO), 1,4,6-androstriatriene-3,17-dione (ATD), and 4-hydroxyandrostenedione.
[0106] Exemplary hormones also include, but are not limited to, tamoxifen (Soltamox, Nolvadex), raloxifene (Evista), megestrol acetate (Megace), leuprolide (Lupron, Lupron Depot, Eligard, Viadur), fulvestrant (Faslodex), letrozole (Femara), triptorelin (Trelstar LA, Trelstar Depot), exemestane (Aromasin), goserelin (Zoladex), bicalutamide (Casodex), anastrozole (Arimidex), fluoxymesterone (Androxy, Halotestin), medroxyprogesterone (Provera, Depo-Provera), estramustine (Emcyt), flutamide (Eulexin), toremifene (Fareston), degarelix (Firmagon), nilutamide (Nilandron), abarelix (Plenixis), or testolactone (Teslac).
[0107] Anti-microtubule or anti-mitotic agents or mitotic inhibitors are phase-specific agents that are active against the microtubules of tumor cells during the M phase or mitotic phase of the cell cycle. Examples of anti-microtubule agents include, but are not limited to, diterpenes and vinca alkaloids. Examples of diterpenoid compounds include, but are not limited to, paclitaxel (e.g., ) and its analogs docetaxel (e.g., Examples of vinca alkaloids include, but are not limited to, vinblastine (e.g. ), vincristine (e.g. ) and vinorelbine (e.g. ).
[0108] Exemplary mitotic inhibitors also include, but are not limited to, paclitaxel (Taxol, Onxol, Abraxane), docetaxel (Taxotere), vincristine (Oncovin, Vincasar PFS), vinblastine (Velban), etoposide (Toposar, Etopophos, VePesid), teniposide (Vumon), ixabepilone (Ixempra), nocodazole, epothilone, vinorelbine (Navelbine), camptothecin (CPT), irinotecan (Camptosar), topotecan (Hycamtin), amsacrine, and lamellaemin D (LAM-D).
[0109] Exemplary multikinase inhibitors include, but are not limited to, sorafenib (Nexavar), sunitinib (Sutent), BIBW2992, E7080, Zd6474, PKC-412, motesanib, and AP24534. Exemplary serine / threonine kinase inhibitors include, but are not limited to, rubustadine, efavirenz / fasudil hydrochloride, flavopiridol, celecoxib (CYC202, Roscovitrine), SNS-032 (BMS-387032), Pkc412, bryostatin, KAI-9803, SF1126, VX-680, Azd1152, Arry-142886 (AZD-6244), SCIO-469, GW681323, CC-401, CEP-1347, and PD 332991.
[0110] Exemplary serine / threonine kinase inhibitors include, but are not limited to, rapamycin (targeting mTOR / FRAP1); rapamycin (targeting mTOR); Certican / Everolimus (targeting mTOR / FRAP1); AP23573 (targeting mTOR / FRAP1); efavirenz / fasudil hydrochloride (targeting RHO); flavopiridol (targeting CDK), celecoxib / CYC202 / Roscovitrine (targeting CDK), SNS-032 / BMS-387032 (targeting CDK), rubestad ( targeting PKC); Pkc412 (targeting PKC); bryostatin (targeting PKC); KAI-9803 (targeting PKC); SF1126 (targeting PI3K); VX-680 (targeting Aurora kinase); Azd1152 (targeting Aurora kinase); Arry-142886 / AZD-6244 (targeting MAP / MEK); SCIO-469 (targeting MAP / MEK); GW681323 (targeting MAP / MEK); CC-401 (targeting JNK); CEP-1347 (targeting JNK); and PD 332991 (targeting CDK).
[0111] Inhibitors of serine / threonine kinases also include MAP kinase cascade blockers, including blockers of Raf kinase (rafk), mitogen- or extracellular-regulated kinase (MEK) and extracellular-regulated kinase (ERK); and protein kinase C family member blockers, including blockers of PKC (α, β, γ, ε, μ, λ, ι, ζ), IkB kinase family (IKKa, IKKb), PKB family kinases, AKT kinase family members and TGFβ receptor kinase. Inhibitors of serine / threonine kinases are also described in J. Biochem. 126, 799 (1999), Biochem. Pharmacol. 60, 1101 (2000); Cancer Surveys 27, 41 (1996); Cancer Treatment Res. 78, 3 (1995); Bioorg. Med. Chem. Letters 10, 223 (2000); U.S. Pat. No. 6,268,391; and Int. J. Cancer 88, 44 (2000).
[0112] Tyrosine kinases (and non-receptor tyrosine kinases) include, but are not limited to, cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (focal adhesion kinase), Bruton's tyrosine kinase, and Bcr-Abl. Inhibitors of non-receptor tyrosine kinases are described in J. Hematotherapy Stem Cell Res. 8, 465 (1999) and Annual Rev. Immunol. 15, 371 (1997).
[0113] Exemplary tyrosine kinase inhibitors also include, but are not limited to, erlotinib (Tarceva), gefitinib (Iressa), imatinib (Gleevec), sorafenib (Nexavar), sunitinib (Sutent), trastuzumab (Herceptin), bevacizumab (Avastin), rituximab (Rituxan), lapatinib (Tykerb), cetuximab (Erbitux), panitumumab (Vectibix), everolimus (Afinitor), alemtuzumab (Campath ... Tocilizumab (Mylotarg), temsirolimus (Torisel), pazopanib (Votrient), dasatinib (Sprycel), nilotinib (Tasigna), vatalanib (Ptk787, ZK222584), icotinib, CEP-701, SU5614, MLN518, XL999, VX-322, Azd0530, BMS-354825, SKI-606CP-690, AG-490, WHI-P154, WHI-P131, AC-220, and AMG888.
[0114] Exemplary VEGF / VEGFR inhibitors include, but are not limited to, bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), ranibizumab, pegaptanib and vandetanib, axitinib, brivanib alanine ((S)-(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate, also known as BMS-582664), motesanib (TST-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide), and pasireotide (also known as SO230).
[0115] Inhibitors of members of the phosphatidylinositol-3 kinase family, including blockers of Pekinese, ATM, DNA-PK and Ku, can also be combined with the compounds of the present application. These inhibitors are discussed in Curr. Opinion Immunol. 8, 412 (1996); Oncogene 17, 3301 (1998); Int. J. Biochem. Cell Biol. 29, 935 (1997); and Cancer Res. 60, 1541 (2000).
[0116] Exemplary kinase inhibitors also include, but are not limited to, bevacizumab (targeting VEGF), BIBW 2992 (targeting EGFR and Erb2), cetuximab / erbitux (targeting Erb1), imatinib / Gleevec (targeting Bcr-Abl, PDGFR and c-Kit), trastuzumab (targeting Erb2), gefitinib / Iressa (targeting EGFR), ranibizumab (targeting VEGF), pegaptanib (targeting VEGF), erlotinib / Tarceva (targeting Erb1), nilotinib (targeting Bcr-Abl), lapatinib (targeting Erb1 and Erb2 / Her2), GW-572016 / lapatinib ditosylate (targeting HER2 / Erb2), panitumumab / Vectib (targeting EGFR), Vandetanib (targeting RET / VEGFR), E7080 (multiple targets, including RET and VEGFR), Herceptin (targeting HER2 / Erb2), PKI-166 (targeting EGFR), Canertinib / CI-1033 (targeting EGFR), Sunitinib / SU-11464 / Sutent (targeting EGFR and FLT3), Matuzumab / Emd7200 (targeting EGFR), EKB-569 (targeting EGFR), Zd6474 (targeting EGFR and VEGFR), PKC-412 (targeting VEGR and FLT3 ), vatalanib / Ptk787 / ZK222584 (targeting VEGR), CEP-701 (targeting FLT3), SU5614 (targeting FLT3), MLN518 (targeting FLT3), XL999 (targeting FLT3), VX-322 (targeting FLT3), Azd0530 (targeting SRC), BMS-354825 (targeting SRC), SKI-606 (targeting SRC), CP-690 (targeting JAK), AG-490 (targeting JAK), WHI-P154 (targeting JAK), WHI-P131 (targeting JAK), sorafil The following are the targets of this trial: Azithromycin / Nexavar (targets RAF kinases, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, KIT, FLT-3, and RET), dasatinib / Sprycel (BCR / ABL and Src), AC-220 (targets Flt3), AC-480 (targets all HER proteins, “pan-HER”), motesanib diphosphate (targets VEGF1-3, PDGFR, and c-kit), denosumab (targets RANKL, inhibits Src), AMG888 (targets HER3), and AP24534 (multiple targets, including Flt3).
[0117] Exemplary microtubule-targeting drugs include, but are not limited to, paclitaxel, docetaxel, vincristine, vinblastine, nocodazole, epothilones, and vinorelbine.
[0118] Exemplary topoisomerase toxic drugs include, but are not limited to, teniposide, etoposide, doxorubicin, camptothecin, daunorubicin, actinomycin, mitoxantrone, amsacrine, epirubicin, and idarubicin.
[0119] Other topoisomerase toxic drugs include topoisomerase II inhibitors, such as epipodophyllotoxins. Examples of epipodophyllotoxins include, but are not limited to, etoposide (VP-16, ) and teniposide (VM-26, ).
[0120] Exemplary taxanes or taxane derivatives include, but are not limited to, paclitaxel and docetaxel.
[0121] Antibody antagonists of receptor kinase ligand binding can also be used as inhibitors. Examples include Imclone C225 EGFR-specific antibody (see Cancer Treat. Rev. 26, 269 (2000)), erbB2 antibody (see Breast Cancer Res. 2, 176 (2000)) and 2CB VEGFR2-specific antibody (see Cancer Res. 60, 5117 (2000)).
[0122] Anti-angiogenic therapeutic agents (including non-receptor MEK angiogenesis inhibitors) can also be combined with the compounds of the present application (e.g., compounds of formula (I)). Anti-angiogenic agents, such as inhibitors of vascular endothelial growth factor (e.g., bevacizumab [Avastin TM ]) and compounds that act through other mechanisms (e.g., linomide, inhibitors of integrin αvβ3 function, endostatin and angiostatin).
[0123] SH2 / SH3 domain blockers can disrupt SH2 or SH3 domain binding in a variety of enzymes or adaptor proteins, including PI3-K p85 subunit, Src family kinases, adaptor molecules (She, Crk, Nek, Grb2) and Ras-GAP. J. Pharm. Toxicol. Methods 34, 125 (1995) discussed SH2 / SH3 domain blockers as anticancer drugs.
[0124] Inhibitors of inositol signaling may include, but are not limited to, phospholipase C blockers and inositol analogs. These signaling inhibitors are described in New Molecular Targets for Cancer Chemotherapy ed., Paul Workman and David Kerr, CRC press 1994, London.
[0125] Inhibitors of Ras oncogenes may include, but are not limited to, inhibitors of farnesyltransferase, geranyl-geranyltransferase, and CAAX protease, as well as antisense oligonucleotides, ribozymes, and immunotherapy. These inhibitors are discussed in J. Biomed. Sci. 7, 292 (2000); Curr. Opin. Lipidology 9, 99 (1998); and BioChim. Biophys. Acta, 1423, 19 (1989).
[0126] Other exemplary general chemotherapeutic agents, anti-tumor agents or anti-proliferative agents also include, but are not limited to, hexamethylmelamine (Hexalen), isotretinoin (Accutane, Amnesteem, Claravis, Sotret), tretinoin (Vesanoid), azacitidine (Vidaza), bortezomib (Velcade), selinexor, asparaginase (Elspar), levamisole (Ergamisol), mitotane (Lysodren), procarbazine (Matulane), pegaspargase (Oncaspar), denileukin (Ontak), porphin (Photofrin), aldesleukin (Proleukin), lenalidomide (Revlimid), bexarotene (Targretin), thalidomide (Thalomid), temsirolimus (Torisel), arsenic trioxide (Trisenox), verteporfin (Visudyne), mimosine (Leucenol), (1M tegafur-0.4M 5-chloro-2,4-dihydroxypyrimidine-1M oxazolidinone potassium) and statins (e.g., lovastatin, atorvastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin).
[0127] Antiviral agents may include, but are not limited to, hepatitis B virus (HBV) inhibitors, hepatitis C virus (HCV) protease inhibitors, HCV polymerase inhibitors, HCV NS4A inhibitors, HCV NS5 A inhibitors, HCV NS5b inhibitors, and human immunodeficiency virus (HIV) inhibitors.
[0128] Antigens or adjuvants may include, but are not limited to, B7 co-stimulatory molecules, interleukin-2, interferon-γ, GM-CSF, CTLA-4 antagonists, OX-40 / OX-40 ligands, CD40 / CD40 ligands, sargramostim, levamisole, vaccinia virus, Bacillus Calmette-Guérin (BCG), liposomes, alum, Freund's complete or incomplete adjuvant, detoxified endotoxin, mineral oil, surfactants such as lipophosphatidylcholine, pluronic polyols, polyanions, peptides, and oil or hydrocarbon emulsions. In one embodiment, adjuvants such as aluminum hydroxide or aluminum phosphate may be added to enhance the ability of the vaccine to trigger, elevate, or prolong an immune response. In one embodiment, additional materials such as cytokines, chemokines, and bacterial nucleic acid sequences, such as CpG, toll-like receptor (TLR) 9 agonists, and additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8, TLR 9, including lipoproteins, LPS, monophosphoryl lipid A, lipoteichoic acid, imiquimod, resiquimod, and other retinoic acid-inducible gene I (RIG-I) agonists, such as poly I:C, can also be used.
[0129] Cytotoxic agents may include, but are not limited to, arsenic trioxide Asparaginase (also known as L-asparaginase and Erwinia L-asparaginase, sold under the trade name and sell).
[0130] Retinoids may include, but are not limited to, alitretinoin (available under the trade name Retinoic acid (all-trans retinoic acid, also known as ATRA, sold under the trade name isotretinoin (13-c / s-retinoic acid, sold under the trade name and and bexarotene (sold under the trade name sell).
[0132] Chemotherapeutic agents may include, but are not limited to, abiraterone acetate, hexamethylmelamine, vinblastine, auristatin, bexarotene, bicalutamide, BMS184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-1-L proline-tert-butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3' , 4'-didehydro-4'deoxy-8'-norvinblastine (norvin-caleukoblastine), docetaxel, doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin, scutellarin, cyclophosphamide, cytarabine, dacarbazine (DTIC, DITC-Dome), dacarbazine, daunomycin, decitabine dolastatin, doxorubicin (adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyurea and Taxanes, ifosfamide, riazole, lonidamine, lomustine (CCNU), MDV3100, mechlorethamine (nitrogen mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef, streptozotocin, mitomycin, methotrexate, taxanes, nilutamide, nivolumab, onapristone, paclitaxel, pembrolizumab, prednimustine, procarbazine, RPR109881, estramustine phosphate, tamoxifen, tasonamine, tacozolin, retinoic acid The invention relates to the combination of rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and hydroxydaunorubicin, and vinblastine, vinblastine, vindesine sulfate, vinflunine, CHOP (i.e., a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone), EPOH (i.e., a combination of etoposide, prednisolone, vincristine, and hydroxydaunorubicin), EPOCH (i.e., a combination of etoposide, prednisolone, vincristine, cyclophosphamide, and hydroxydaunorubicin), and R-EPOCH (i.e., a combination of rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and hydroxydaunorubicin).
[0133] Exemplary cytidine analogs include, but are not limited to, gemcitabine, azacytidine (eg, 5-azacytidine), and arabinoside cytosine (cytarabine, araC, Cytosar).
[0134] Other therapeutic agents may include, but are not limited to, inhibitors of cell cycle signaling, pro-apoptotic agents, PARP inhibitors, checkpoint therapeutics, and immunomodulators.
[0135] Cell cycle signal transduction inhibitors inhibit molecules involved in the control of the cell cycle. A family of protein kinases called cyclin-dependent kinases (CDKs) and their interaction with a family of proteins called cyclins control the progression of the eukaryotic cell cycle. Several inhibitors of cell cycle signal transduction are being developed. For example, examples of cyclin-dependent kinases (including CDK2, CDK4, and CDK6) and their inhibitors are described in Exp. Opin. Ther. Patents 10, 215 (2000).
[0136] Therapeutic agents used in pro-apoptotic regimens (eg, bcl-2 antisense oligonucleotides) can also be used in combination with the compounds of the present application (eg, compounds of formula (I)).
[0137] As used herein, PARP inhibitors refer to a group of drug inhibitors of poly ADP ribose polymerase (PARP). Exemplary PARP inhibitors include, but are not limited to, Olaparib (AZD-2281, Astra Zeneca ), Rucaparib (PF-01367338, Clovis Oncology ), Niraparib (MK-4827, Tesaro ), talazoparib (BMN-673), veliparib (ABT-888), olaparib (AZD-2281), olaparib TOPARP-A, rucaparib (PF-01367338, AG014699), CEP 9722, E7016 (developed by Eisai), BGB-2901, iniparib (BSI201), 3-aminobenzamide, and pamiparib.
[0138] Reagents used in immunotherapy regimens can also be used in combination with the compounds of the present application (e.g., compounds of formula (I)). Immunotherapeutic methods include ex vivo and in vivo methods for increasing the immunogenicity of patient tumor cells (e.g., transfection with cytokines (e.g., interleukin 2, interleukin 4, or granulocyte-macrophage colony stimulating factor)), methods for reducing T cell energy, methods using transfected immune cells (e.g., cytokine-transfected dendritic cells), methods using cytokine-transfected tumor cell lines, and methods using anti-idiotypic antibodies.
[0139] As used herein, checkpoint inhibitor therapy refers to a form of cancer treatment immunotherapy that targets immune checkpoints, which are key regulators of the immune system that stimulate or inhibit the action of the immune system, which allows tumors to protect themselves from attack by the immune system. Checkpoint therapy can block inhibitory checkpoints and restore immune system function.
[0140] As used herein, "immunomodulator" or "immunomodulator" refers to any substance that affects the immune system, including monoclonal antibodies. Immunomodulators and immunomodulators may include, but are not limited to, checkpoint inhibitors. Immunomodulators can be used as anti-tumor agents for the treatment of cancer. For example, immunomodulators include, but are not limited to, anti-CTLA-4 antibodies, such as ipilimumab (YERVOY) and anti-PD-1 antibodies (Opdivo / nivolumab and Keytruda / pembrolizumab). Other immunomodulators include, but are not limited to, ICOS antibodies, OX-40 antibodies, PD-L1 antibodies, LAG3 antibodies, TIM-3 antibodies, 41BB antibodies, and GITR antibodies. CLTA-4 and PD-1 pathways are important negative regulators of immune responses. Activated T cells upregulate CTLA-4, which binds to antigen presenting cells and inhibits T cell stimulation, IL-2 gene expression, and T cell proliferation. PD-1 binds to active T cells and inhibits T cell activation. PD-1 antagonists have shown anti-tumor effects. CTLA-4 and PD-1 pathway antagonists that can be used in combination with the compounds of the present application include ipilimumab, tesimumab, nivolumab, pembrolizumab, CT-011, AMP-224 and MDX-1106.
[0141] As used herein, PD-1 inhibitors and PD-L1 inhibitors refer to a group of checkpoint inhibitors or immune checkpoint inhibitors for the treatment of cancer. PD1 and PD-L1 are proteins present on the surface of cells. PD-1 and PD-L1 inhibitors inhibit the binding of programmed death ligand (PD-L1) to its receptor programmed cell death protein 1 (PD-1). Exemplary PD-1 and / or PD-L1 inhibitors include but are not limited to nivolumab (Opdivo), pembrolizumab (MK-3475 or lambrolizumab, Keytruda), atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), tislelizumab, pidilizumab, AMP-224, AMP-514, PDR001, simiprizumab, BMS-936559 and CK-301.
[0142] In some embodiments, the PD-1 or PD-L1 inhibitor is nivolumab (Opdivo), pembrolizumab (MK-3475 or lambrolizumab, Keytruda), atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), or tislelizumab.
[0143] Anti-PD-L1 antibodies and methods for preparing them are known in the art. Such anti-PD-L1 antibodies may be polyclonal or monoclonal, and / or recombinant, and / or humanized. Exemplary PD-L1 antibodies are disclosed in U.S. Patent Nos. 8,217,149, 8,383,796, 8,552,154, 9,212,224, and 8,779,108, and U.S. Patent Application Publication Nos. 20110280877, 20140341902, and 20130045201. Other exemplary antibodies and methods of use of PD-L1 (also known as CD274 or B7-H1) are disclosed in U.S. Patent Nos. 7,943,743, 8,168,179, and 7,595,048; WO2014055897, WO2016007235, and U.S. Patent Application Publication Nos. 20130034559 and 20150274835. In one embodiment, the anti-PD-L1 antibody is BMS-936559 (MDX-1105), MPDL3280A (RG7446), MEDI4736, TECENTRIQ TM (atezolizumab), YW243.55.S70, MPDL3280A, BMS-936559, MEDI4736 or MSB0010718C, or a V described in WO2013019906 H and V L Antibodies (e.g., SEQ ID NOs: 21 and 24 therein). Examples of anti-PD-L1 antibodies and methods for making them are also described in WO 2010077634, WO 2007005874, WO2011066389, WO 2013019906, WO 2010077634, U.S. Pat. Nos. 8,217,149 and 8,383,796, and U.S. Patent Application Publication No. 2013034559.
[0144] PD-1 antagonists or PD-1 inhibitors refer to any compound or biological molecule that prevents PD-L1 expressed on cancer cells from binding to PD-1 expressed on immune cells (T cells, B cells, or NKT cells), and preferably also prevents PD-L2 expressed on cancer cells from binding to PD-1 expressed on immune cells. Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279, and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274, and B7-H for PD-L1; PDCD1L2, PDL2, B7-DC, Btdc, and CD273 for PD-L2. The human PD-1 amino acid sequence can be found in NCBI locus No. NP_005009. Human PD-L1 and PD-L2 amino acid sequences can be found in NCBI genome Nos. NP_054862 and NP_079515, respectively.
[0145] PD-1 antagonists may include, but are not limited to, monoclonal antibodies (mAbs) or antigen-binding fragments thereof that specifically bind to PD-1 or PD-L1, preferably specifically bind to human PD-1 or human PD-L1. mAbs may be human antibodies, humanized antibodies, or chimeric antibodies, and may include human constant regions. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in some embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen-binding fragment is selected from Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.
[0146] Examples of mAbs that bind to human PD-1 are described in U.S. Pat. Nos. 7,488,802, 7,521,051, 8,008,449, 8,354,509, and 8,168,757, WO 2004004771, WO 2004072286, WO 2004056875, and U.S. Patent Application Publication No. 20110271358. In one embodiment, anti-human PD-1 mAbs used as PD-1 antagonists include: MK-3475, nivolumab, humanized antibodies h409A11, h409A16, and h409A17, which are described in WO2008156712 and AMP-514.
[0147] Other PD-1 antagonists used in any aspects and embodiments of the present application include immunoadhesins that specifically bind to PD-1, preferably to human PD-1, such as fusion proteins comprising an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region of an immunoglobulin molecule, such as an Fc region. Examples of immunoadhesion molecules that specifically bind to PD-1 are described in WO 2010027827 and WO 2011066342. In one embodiment, the PD-1 antagonist includes AMP-224 (also known as B7-DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.
[0148] In one embodiment, the anti-PD-1 antibody is KEYTRUDA / pembrolizumab disclosed in U.S. Pat. No. 8,168,757 or Opdivo / nivolumab disclosed in U.S. Pat. No. 8,008,449 (also known as BMS-936558, MDX-1106, and ONO-4538).
[0149] In one embodiment, the CTLA-4 antagonist is Yervoy (ipilimumab), which is described in U.S. Pat. Nos. 6,984,720 and 7,605,238.
[0150] Other examples of other therapeutic agents (anti-tumor agents) that are combined or co-administered with the compounds of the present application (e.g., compounds of formula (I)) include antibodies against ICOS. Agonist antibodies against ICOS or ICOS binding proteins are disclosed in WO2012013004, WO 2014033327, WO 2016120789, U.S. Patent Application Publication Nos. 20160215059 and US20160304610, for example, SEQ ID NOs: 1-6 disclosed in WO 2016120789 or their direct equivalents, V disclosed in WO2016120789 comprising an amino acid sequence at least 90% identical to SEQ ID NO: 7 H domain, and / or a V disclosed in WO2016120789 comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 L Structural domain.
[0151] Other examples of other therapeutic agents (anti-tumor agents) for combination or co-administration with the compounds of the present application (e.g., compounds of formula (I)) include antibodies against OXO40. The antibodies are described in WO 2012027328, WO 2013028231 (e.g., comprising a V sequence having at least 90% identical sequence to SEQ ID NO: 10). Land / or a V having a sequence at least 90% identical to SEQ ID NO: 4 H of antibodies).
[0152] Other examples of other therapeutic agents combined or co-administered with the compounds of the present application (e.g., compounds of formula (I)) include immunostimulants. As used herein, immunostimulants refer to any agent capable of stimulating the immune system. Immunostimulants used herein include, but are not limited to, vaccine adjuvants, such as Toll-like receptor agonists, T cell checkpoint blockers (e.g., mAbs of PD-1 and CTL4), and T cell checkpoint agonists (e.g., agonist mAbs of OX-40 and ICOS).
[0153] In one embodiment, TLR agonists include but are not limited to Pam3Cys, a TLR1 / 2 agonist; CFA, a TLR2 agonist; MALP2, a TLR2 agonist; Pam2Cys, a TLR2 agonist; FSL-1, a TLR-2 agonist; Hib-OMPC, a TLR-2 agonist; polyinosinic acid:polycytidylic acid (Poly I:C), a TLR3 agonist; polyadenosine-polyuridine (poly AU), a TLR3 agonist; polyinosinic acid-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose (Hiltonol), a TLR3 agonist; bacterial flagellin, a TLR5 agonist; imiquimod, a TLR7 agonist; resiquimod, a TLR7 / 8 agonist; loxoribine, a TLR7 / 8 agonist; and unmethylated CpG dinucleotide (CpG-ODN), a TLR9 agonist. Other TLR agonists include, but are not limited to, aminoalkyl glucosamine phosphates (AGPs). An example of a naturally occurring TLR4 agonist is bacterial LPS. An example of a semisynthetic TLR4 agonist is monophosphoryl lipid A (MPL). U.S. Patents Nos. 7,129,219, 6,525,028, and 6,911,434 disclose other AGP derivatives.
[0154] In one embodiment, the immunostimulant used in combination with the compounds of the present application (e.g., compounds of formula (I)) is a TLR4 agonist. In one embodiment, the TLR4 agonist is CRX-601, CRX-527, or CRX 547. Other embodiments include AGP, such as CRX 602 or CRX 526.
[0155] In addition, the compounds of the present application (e.g., compounds of formula (I)) can be combined with other therapeutic agents, which can stimulate the immune system to respond to cancer antigens present on inactivated tumor cells due to their adjuvant properties. Such adjuvants include, but are not limited to, lipids, liposomes, inactivated bacteria that induce innate immunity (e.g., inactivated or attenuated Listeria monocytogenes), compositions that mediate innate immune activation through (NOD)-like receptors (NLR), retinoic acid-inducible gene (RIG)-I-like receptors and / or C-type lectin receptors (CLR). Examples of PAMPs include lipoproteins, lipopolypeptides, peptidoglycans, yeast polysaccharides, neisseria porins, flagellin, profillin, galactosylceramide, muramyl dipeptide. Peptidoglycans, lipoproteins, and lipoteichoic acid are cell wall components of gram-positive bacteria. Most bacteria express lipopolysaccharides, with MPL as an example. Flagellin refers to the structural component of bacterial flagella secreted by pathogens and commensal bacteria, rt-galactosylceramide (rt-GalCer) is an activator of natural killer T (NKT) cells. Muramyl dipeptide is a biologically active peptidoglycan motif shared by all bacteria.
[0156] Other examples of other therapeutic agents that can be combined or co-administered with the compounds of the present application (e.g., compounds of formula (I)) include IDO inhibitors (e.g., Epacadostat disclosed in U.S. Pat. No. 8,034,953), CD73 inhibitors, and A2a and A2b adenosine antagonists.
[0157] In one embodiment, the compounds may be administered in combination with one or more separate pharmaceutical agents, such as chemotherapeutic agents, immunotherapeutic agents, or adjunctive therapeutic agents.
[0158] The compounds of the present application (eg, compounds of formula (I)) can be used in combination with at least one other therapeutic agent for preventing or treating bacterial and viral infections. Examples of such agents include, but are not limited to, polymerase inhibitors, such as those disclosed in WO2004037818 and WO 2006045613; JTK-003, JTK-019, NM-283, HCV-796, R-803, R1728, R1626, and WO 2006018725, WO 2004074270, WO 2003095441, U.S. Patent Application Publication No. 20050176701, WO 2006020082, WO 2005080388, WO 2004064925, WO 2004065367, WO2003007945, WO 2002004425, WO 2005014543, WO 2003000254, EP 1065213, WO2001047883, WO 2002057287, WO 2002057245; replication inhibitors such as acyclovir, famciclovir, ganciclovir, cidofovir, lamivudine and similar agents; protease inhibitors such as HIV protease inhibitors saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, becanavir, atazanavir, tipranavir, palinavir, rasinavir, and HCV protease inhibitor BILN20 61. VX-950, SCH503034 and similar agents; nucleoside and nucleotide reverse transcriptase inhibitors, such as zidovudine, didovudine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabin, ne), tenofovir disoproxil fumarate, tenofovir alafenamide fumarate / hemifumarate and similar agents; non-nucleoside reverse transcriptase inhibitors (including agents with antioxidant activity, such as immunocal, oltipraz, etc.), such as nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, TMC-278, TMC-125, etravirine, rilpivirine and similar agents; entry inhibitors, such as enfuvirtide (T-20), T-1249, PRO-542, PRO-140, TNX-355, BMS-806, 5-Helix and similar agents; integrase inhibitors, such as dolutegravir, elvitegravir, raltegravir L-870, 180 and similar agents; sprouting inhibitors, such as PA-344 and PA-457 and similar agents;Chemokine receptor inhibitors, such as vicriviroc (Sch-C), Sch-D, TAK779, maraviroc (UK-427,857), TAK449, and WO 2002074769, WO 20040054974, WO 2004055012, WO 2004055010, WO 2004055016, WO 2004055011, and Chemokine receptor inhibitors and similar agents described in WO2004054581; pharmacokinetic enhancers, such as cobicistat; neuraminidase inhibitors, such as CS-8958, zanamivir, oseltamivir, peramivir and similar agents; ion channel blockers, such as amantadine or rimantadine and similar agents; interfering RNA and antisense oligonucleotides, such as ISIS-14803 and similar agents; and antiviral agents with unknown mechanisms of action, such as antiviral agents disclosed in WO 2005105761, WO2003085375, WO 2006122011, ribavirin and similar agents. ;
[0159] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with at least one other therapeutic agent that can be used to treat Kaposi's sarcoma-associated herpes virus infection (KSHV and KSHV-associated), including but not limited to chemotherapeutic agents (e.g., bleomycin, vinblastine, vincristine, cyclophosphamide, prednisone, alitretinoic acid) and liposomal anthracyclines (e.g., doxorubicin, daunorubicin), immunotherapeutic agents (rituximab, tuximab, siltuximab) and other agents (e.g., paclitaxel and rapamycin).
[0160] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with at least one other therapeutic agent that can be used to treat TB infection (Mycobacterium tuberculosis) and tularemia (Francisco tularensis), including but not limited to first-line oral agents isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, rifabutin; injectable agents, including kanamycin, amikacin, capreomycin, streptomycin; fluoroquinolones, including levofloxacin, moxifloxacin, ofloxacin; oral antibacterial agents, para-aminosalicylic acid, cycloserine, acid, terizidone, ethionamide, prothionamide; SQ-109PNU-100480, rifapentine-linezolid, PA-824AZD5847, gatifloxacin-moxifloxacin, Sirturo (bedaquiline), delamanid (OPC-67683), and drugs with unknown mechanisms of action for the treatment of drug-resistant TB, including clofazimine, linezolid, amoxicillin / clavulanate thioacetate, imipenem / cilastatin, high-dose isoniazid, clarithromycin, and ciprofloxacin.
[0161] The compounds of the present application (eg, compounds of formula (I)) may be combined with at least one antimycobacterial agent (eg, isoniazid (INH), ethambutol Rifampin and pyrazinamide (PZA)), bactericidal antibiotics (such as rifabutin or rifapentine ), aminoglycosides Fluoroquinolones (levofloxacin, moxifloxacin, ofloxacin), thioamides (ethionamide), cyclosporine Para-aminosalicylic acid Cycloserine Kanamycin Streptomycin, viomycin, capreomycin ), Betaquiline Fumarate Oxazolidinone PNU-100480 or delamanid (OPC-67683) in combination.
[0162] The compounds of the present application (eg, compounds of formula (I)) can be used in combination with at least one other therapeutic agent useful for treating Chlamydia, including but not limited to azithromycin, doxycycline, erythromycin, levofloxacin, and ofloxacin.
[0163] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with at least one other therapeutic agent that can be used to treat Plasmodium infection, including but not limited to chloroquine, atovaquone-proguanil, artemether-lumefantrine, mefloquine, quinine, quinidine, doxycycline, clindamycin, artesunate and primaquine.
[0164] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with glutamate blockers (e.g., riluzole) in the treatment of amyotrophic lateral sclerosis (ALS). ), Quinidine Anticholinergics ( Scopolamine patch (Transderm )), sympathomimetics (pseudoephedrine), mucolytics (guaifenesin), or analgesics (tramadol ); Ketorolac Morphine; or fentanyl patch ) in combination.
[0165] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with corticosteroids (prednisone, methylprednisolone), interferon β1-A, Pegylated interferon beta-1A Glatiramer acetate Glatiramer acetate ( dimethyl fumarate Fingolimod ); teriflunomide Dalfampridine Daclizumab (Zinbryta); Alemtuzumab Natalizumab Mitoxantrone hydrochloride Use in combination.
[0166] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with one or more vaccines or immunogenic antigens for preventing or treating viral infections. The vaccine or immunogenic antigen includes, but is not limited to, pathogen-derived proteins or particles, such as attenuated viruses, viral particles, and viral proteins commonly used as immunogenic substances. Examples of viruses and viral antigens include, but are not limited to, poliovirus, Coronavirus family and coronavirus, rhinovirus (all subtypes), adenovirus (all subtypes), hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, human papillomavirus (including all subtypes), rabies virus, human T-lymphotropic virus (all subtypes), rubella virus, mumps virus, coxsackie virus A (all subtypes), coxsackie virus B (all subtypes), human enterovirus, herpes virus (including macrophages, herpes simplex virus, varicella zoster virus, human immunodeficiency virus (HIV) (all subtypes), Epstein-Barr virus, reovirus (all subtypes), filoviruses (including Marburg virus and Ebola virus) (all strains), adenoviruses (including lymphocytic choriomeningitis virus, Lassa virus, Junin virus and Machupo virus), arboviruses (including West Nile virus, dengue virus (all serotypes), Zika virus virus, Colorado tick fever virus, Sindbis virus), Togaviridae, Flaviviridae, Bunyaviridae, Reoviridae, Rhabdoviridae, Orthomyxoviridae, Poxviruses (including orthopoxviruses (smallpox virus, monkeypox virus, vaccinia virus, cowpox virus), yatapoxvirus (Tenapox virus, Yaba monkey tumor virus), parapoxvirus, molluscivirus (molluscipoxvirus), yellow fever, Hantaviruses (including Hantavirus, Seoul virus, Dobra virus, The virus contains 24 viruses, including Sinombre, Puumala and Dobra-like Sarima viruses, human parainfluenza and influenza viruses (all types), influenza A (H1N1) and swine influenza viruses, respiratory syncytial virus (all subgroups), rotaviruses (including human rotavirus AE, bovine rotavirus, rhesus monkey rotavirus), polyomaviruses (including simian virus 40), JC virus, BK virus, Coltiviruses, Eyach virus, Caliciviruses and Parvoviridae (including Dependovirus, Parvovirus and Erythrovirus).
[0167] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with at least one other therapeutic agent that can be used to prevent or treat viral infections, such as immunotherapy (e.g., interferon or other cytokines / chemokines, cytokine / chemokine receptor modulators, cytokine agonists or antagonists, and similar agents); and therapeutic vaccines, anti-fibrotic agents, anti-inflammatory agents (e.g., corticosteroids or NSAIDs (non-steroidal anti-inflammatory agents) and similar agents).
[0168] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with other anti-inflammatory agents, including oral or topical corticosteroids, anti-TNF agents, 5-aminosalicylic acid and mesalazine preparations, hydroxychloroquine, thiopurines, methotrexate, cyclophosphamide, cyclosporin, calcineurin inhibitors, mycophenolic acid, mTOR inhibitors, JAK inhibitors, Syk inhibitors, anti-inflammatory biologics (including anti-IL6 biologics, anti-IL1 agents, anti-IL17 biologics, anti-CD22, anti-integrin agents, anti-IFNa, anti-CD20 or CD4 biologics) and other cytokine inhibitors or biologics directed against T cell or B cell receptors or interleukins.
[0169] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with at least one other therapeutic agent, including but not limited to corticosteroids (e.g., prednisolone ( Orapred, Millipred, Omnipred, Econopred, Flo-Pred)), immunosuppressants (such as methotrexate Dexamethasone Mycophenolate mofetil B cell therapy (belimumab B cell inhibitors ( (anti-CD22), SBI-087 (anti-CD20), anti-BAFF antibody (LY2127399, A623), ), azathioprine Triamcinolone acetonide Hydroxychloroquine Thalidomide Immunoglobulin therapy Anti-interferon-α therapy ( IFN Kinoid), TLR7 and TLR9 blockers (IMO-3100), anti-cytokine therapy (anti-IL6 (CNTO-136), anti-interferon-γ (AMG 811), immunomodulatory therapy (Lupuzor TM , Abatacept, AMG557, laquinimod, paquimod, leflunomide, anti-ICOS (Medi-570), anti-CD40 ligand antibody (CDP7657)) and / or platelet aggregation inhibitor (aspirin).
[0170] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with alkylating agents (cyclophosphamide, ), anti-rheumatic drugs, anti-CD20 antibodies and anti-TNF inhibitors Use in combination.
[0171] The compounds of the present application (eg, compounds of formula (I)) can be used in combination with ixekizumab, teikizumab (MK-3222), or secukinumab (AIN457), for example, in the treatment of psoriasis.
[0172] The second agent can be selected from inhaled corticosteroids, long-acting beta agonists, a combination of inhaled corticosteroids and long-acting beta agonists, short-acting beta agonists, leukotriene modifiers, anti-IgE, methylxanthine bronchodilators, mast cell inhibitors, and long-acting muscarinic antagonists. The compounds of the present application can be used in combination with inhaled corticosteroids (ICS), such as fluticasone propionate, in the treatment of asthma. Beclomethasone dipropionate Budesonide (Pulmicort), triamcinolone Flunisolide Mometasone furoate Ciclesonide ), long-acting beta-agonists (LABAs, such as formoterol fumarate Salmeterol Xinafoate ), ICS and LABA combinations (eg, fluticasone furoate and vilanterol (Breo ), formoterol / budesonide inhaler Beclomethasone dipropionate / Formoterol and fluticasone propionate / salmeterol ), short-acting beta-agonists (SABAs), such as albuterol sulfate ( Proventil Ventolin Inhalation solution), levsalbutamol tartrate ( HFA), ipratropium / salbutamol Ipratropium bromide ( HFA), leukotriene modifiers (such as montelukast sodium Zafirlukast or Qiliutong and anti-IgE (eg, omalizumab ), methylxanthine bronchodilators (eg, theophylline Mast cell inhibitors (eg, cromolyn sodium Nedocromil sodium ), long-acting muscarinic antagonists (LAMA), such as mometasone furoate / formoterol fumarate dihydrate ) in combination.
[0174] The second agent may also include, but is not limited to, protein tyrosine kinase inhibitors (masitinib), CRTH2 / D-prostaglandin receptor antagonists (AMG 853), indacaterol Epinephrine inhalation aerosol (E004), fluticasone furoate / fluticasone propionate, vilanterol inhaler / fluticasone furoate powder (Relovair TM ), Fluticasone Propionate / Eformoterol Fumarate Dehydrate Reslizumab, salbutamol dry powder inhaler, tiotropium bromide Formoterol / Budesonide Fluticasone furoate Vectura's VR506, levitra (RG3637), and a combined phosphodiesterase (PDE)-3 and (PDE)-4 inhibitor (RPL554).
[0175] The second agent may also include, but is not limited to, a combination of a long-acting beta agonist, a long-acting inhaled anticholinergic or muscarinic antagonist, a phosphodiesterase inhibitor, an inhaled corticosteroid, a long-acting beta agonist, a short-acting beta agonist, and an inhaled corticosteroid. For example, in the treatment of COPD, the compounds of the present application may be combined with LABA (e.g., salmeterol xinafoate) umeclidinium / vilanterol (Anoro )、umeclidinium(Incruse ), Arformoterol tartrate Formoterol Fumarate Inhalation Powder Indacaterol Maleate or fluticasone propionate / efomoterol fumarate dehydrate ), long-acting inhaled anticholinergics (or muscarinic antagonists, such as tiotropium and aclidinium bromide Phosphodiesterase (PDE-r) inhibitors (e.g. roflumilast, ), ICS / LABA combinations (e.g., fluticasone furoate and vilanterol (Breo ), Fluticasone Propionate / Salmeterol Budesonide / Formoterol Mometasone / Formoterol Ipratropium bromide / salbutamol sulfate Salbutamol / ipratropium (Combivent )), SABA (such as ipratropium bromide and salbutamol sulfate ), ICS (such as budesonide and fluticasone propionate Beclomethasone dipropionate (QVAR) is used in combination.
[0176] For example, in the treatment of COPD, other agents that may be used in combination with the compounds of the present disclosure (e.g., compounds of formula (I)) include, but are not limited to, SCH527123 (CXCR2 antagonist), glycopyrrolate (NVA237), ), glycopyrrolate and indacaterol maleate ((QVA149) ), glycopyrrolate and formoterol fumarate (PT003), indacaterol maleate (QVA149), olodaterol Tiotropium bromide / Odatero and aclidinium / formoterol inhaler.
[0177] The second agent may include, but is not limited to, oral corticosteroids, antithymocyte globulin, thalidomide, chlorambucil, calcium channel blockers, topical lubricants, ACE inhibitors, serotonin reuptake inhibitors, endothelin-1 receptor inhibitors, antifibrotic agents, proton pump inhibitors, or imatinib, ARG201, and tocilizumab.
[0178] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with oral corticosteroids (e.g., prednisolone ( Orapred, Millipred, Omnipred, Econopred, Flo-Pred), immunosuppressants (such as methotrexate Cyclosporine Antithymocyte globulin Mycophenolate mofetil Cyclophosphamide FK506 (tacrolimus), thalidomide Chlorambucil Azathioprine ), calcium channel blockers (such as nifedipine or nicardipine Topical lubricants (nitroglycerin ointment), ACE inhibitors (such as lisinopril Diltiazem ( Cardizem Cardizem )), serotonin reuptake inhibitors (such as fluoxetine ), endothelin-1 receptor inhibitors (e.g. bosentan Epoprostenol ), antifibrotic agents (e.g. colchicine Para-aminobenzoic acid (PABA), dimethyl sulfoxide (DMSO), and D-penicillamine Interferon alpha and interferon gamma (INF-g), proton pump inhibitors (such as omeprazole Metoclopramide Lansoprazole Esomeprazole Pantoprazole Rabeprazole ) or imatinib ARG201 (arGentis Pharmaceutical), belimumab Tocilizumab Use in combination.
[0179] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with anti-rheumatic drugs (hydroxychloroquine and ), cholinergic agonists JAK inhibitors and anti-TNF therapy Use in combination.
[0180] The second agent may include, but is not limited to, ciliary neurotrophic growth factor or a gene transfer agent. For example, in the treatment of retinitis pigmentosa, the compound of the present application may be combined with ciliary neurotrophic growth factor (NT-501-CNTF) or a gene transfer agent. Use in combination.
[0181] The second agent may include, but is not limited to, a trivalent (IIV3) inactivated influenza vaccine, a quadrivalent (IIV4) inactivated influenza vaccine, a trivalent recombinant influenza vaccine, a quadrivalent attenuated live influenza vaccine, an antiviral agent, or an inactivated influenza vaccine. For example, in the treatment of influenza, the compounds of the present application (e.g., compounds of formula (I)) may be combined with a trivalent (IIV3) inactivated influenza vaccine (e.g., Quadrivalent (IIV4) inactivated influenza vaccine (eg Quadrivalent, Quadrivalent, Quadrivalent), trivalent recombinant influenza vaccine (e.g. ), quadrivalent live attenuated influenza vaccine (e.g. Quadrivalent), antiviral agents (such as oseltamivir Zanamivir Rimantadine or amantadine )or Fludase, Preflucel or Use in combination.
[0182] The compounds of the present application (e.g., compounds of formula (I)) can be used in combination with antibiotics (e.g., β-lactam cephalosporins ( etc.), nafcillin Sulfonamides (sulfamethoxazole Azole and trimethoprim Sulfasalazine Acetylsulfadiazine etc.) or vancomycin ) in combination.
[0183] The second agent may include, but is not limited to, a topical immunomodulator or calcineurin inhibitor, a topical corticosteroid, an oral corticosteroid, gamma-interferon, an antihistamine, or an antibiotic. The compounds of the present application (e.g., compounds of formula (I)) may be used in combination with topical immunomodulators or calcineurin inhibitors (e.g., pimecrolimus) in the treatment of, for example, atopic dermatitis. or tacrolimus ointment ), topical corticosteroids (eg, hydrocortisone Betamethasone Flurandrenolide Fluticasone Triamcinolone acetonide Fluocinolone acetonide and clobetasol ), oral corticosteroids (eg, hydrocortisone Methylprednisolone or prednisolone Immunosuppressants (eg, cyclosporine or interferon-γ (Alferon Intron A. )), antihistamines (used to treat itchy skin, such as ), antibiotics (such as the penicillin derivative flucloxacillin or dicloxacillin Erythromycin ( etc.)), nonsteroidal immunosuppressants (such as azathioprine Methotrexate Cyclosporine Mycophenolate mofetil ) in combination.
[0184] On the other hand, the second agent may include, but is not limited to, a cytokine, such as G-CSF (granulocyte colony stimulating factor). On the other hand, a compound of the invention (e.g., a compound of formula (I)) or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, may be administered in combination with radiation therapy. Radiation therapy may also be administered in combination with a compound of the invention (e.g., a compound of formula (I)) and another chemotherapeutic agent as part of a multidrug therapy as described herein. In another aspect, the compounds of the invention (e.g., compounds of formula (I)), or pharmaceutically acceptable salts, prodrugs, metabolites, analogs or derivatives thereof, can be combined with standard chemotherapy, such as, but not limited to, CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, doxorubicin and 5-fluorouracil), AC (doxorubicin and cyclophosphamide), FEC (5-fluorouracil, epirubicin and cyclophosphamide), ACT or ATC (doxorubicin, cyclophosphamide and paclitaxel), rituximab, capecitabine, cisplatin (CDDP), carboplatin, TS-1 (tegafur, gimeracil and oxazide potassium, in a molar ratio of 1:0.4:1), camptothecin-11 (CPT-11, irinotecan or Camptosar TM ) or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone) in combination.
[0185] In some embodiments, the compounds of the invention (e.g., compounds of formula (I)) or pharmaceutically acceptable salts, prodrugs, metabolites, polymorphs or solvates thereof, may be administered together with inhibitors of enzymes (e.g., receptor or non-receptor kinases). The receptor and non-receptor kinases of the invention are, for example, tyrosine kinases or serine / threonine kinases. The kinase inhibitors of the invention are small molecules, polynucleic acids, polypeptides or antibodies.
[0186] Pharmaceutical composition
[0187] The present application also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient or carrier.
[0188] A "pharmaceutical composition" is a preparation containing a compound of the present invention in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a bottle. The amount of the active ingredient (e.g., a preparation of a disclosed compound or a pharmaceutically acceptable salt thereof, a tautomer, a prodrug, a solvate, a metabolite, a polymorph, an analog, or a derivative) in the unit dose composition is an effective amount and varies according to the specific treatment involved. It will be appreciated by those skilled in the art that it is sometimes necessary to make routine changes to the dosage according to the age and condition of the patient. The dosage also depends on the route of administration.
[0189] A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, oral, sublingual, intrathoracic, intrathecal, intranasal, etc. Dosage forms for topical or transdermal administration of the compounds of the present application include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any preservatives, buffers, or propellants required.
[0190] As used herein, the phrase "pharmaceutically acceptable" refers to compounds, materials, compositions, carriers and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0191] "Pharmaceutically acceptable excipient" refers to an excipient that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, and not biologically or otherwise undesirable, and includes excipients that can be used for veterinary use and human pharmaceutical use. "Pharmaceutically acceptable excipient" as used in the specification and claims includes one or more such excipients.
[0192] The pharmaceutical composition of the present application is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral administration, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous applications may include the following ingredients: sterile diluents, such as water for injection, saline solutions, fixed oils, polyethylene glycols, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates, or phosphates, and agents for adjusting tension, such as sodium chloride or glucose. pH can be adjusted with an acid or base (e.g., hydrochloric acid or sodium hydroxide). Parenteral preparations can be contained in ampoules, disposable syringes, or multiple dose bottles made of glass or plastic.
[0193] The compounds or pharmaceutical compositions of the present application can be applied to subjects by many well-known methods currently used for chemotherapy. For example, in order to treat cancer, the compounds of the present application can be injected directly into a tumor, injected into the bloodstream or body cavity, or orally or administered through the skin using a patch. The selected dose should be sufficient to constitute an effective treatment, but not so high as to cause unacceptable side effects. During and after treatment for a reasonable period of time, it is preferred to closely monitor the patient's disease state (e.g., cancer, precancer, etc.) and health status.
[0194] As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that is used to treat, ameliorate or prevent an established disease or condition, or that exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any test method known in the art. The exact effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount in a particular case can be determined by routine experimentation within the skill and judgment of the clinician.
[0195] For any compound, the therapeutically effective amount can be estimated initially in cell culture assays (e.g., tumor cells) or in animal models (usually rats, mice, rabbits, dogs, or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. This information can be used to determine effective doses and routes of administration in humans. Therapeutic / preventive efficacy and toxicity (e.g., ED) 50 (therapeutically effective dose for 50% of the population) and LD 50 The dose lethal to 50% of the population can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio, LD 50 / ED 50Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
[0196] Dosage and administration are adjusted to provide adequate levels of active agent or to maintain the desired effect. Factors that may be considered include the severity of the disease state, the general health of the subject, the age, weight and sex of the subject, diet, time and frequency of administration, drug combination, reaction sensitivity and tolerance / response to treatment. Long-acting pharmaceutical compositions may be administered every 3-4 days, weekly or biweekly, depending on the half-life and clearance rate of the particular formulation.
[0197] The pharmaceutical composition comprising the active compound (i.e., formula (I) compound) of the present application can be manufactured in a generally known manner, for example, by conventional mixing, dissolving, granulating, making dragees, grinding, emulsifying, encapsulating, embedding or freeze drying processes. One or more pharmaceutically acceptable carriers can be used to prepare the pharmaceutical composition in a conventional manner, and the carrier comprises excipients and / or adjuvants that contribute to processing the active compound into a pharmaceutically acceptable preparation. Of course, suitable preparations depend on the selected route of administration.
[0198] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should maintain fluidity within the range of easy injection. It must remain stable under production and storage conditions, and must prevent the contamination of microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium comprising, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Suitable fluidity can be maintained by, for example, using a coating (such as lecithin), by maintaining the required particle size (with respect to dispersions) and by using a surfactant. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols (such as mannitol, sorbitol), sodium chloride. The extended absorption of the injectable composition can be achieved by adding an agent (such as aluminum monostearate and gelatin) that delays absorption in the composition.
[0199] Sterile injections can be prepared by mixing the required amount of active compound with one or more of the ingredients listed above (optionally) in an appropriate solvent, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile carrier comprising a basic dispersion medium and other required ingredients listed above. For sterile powders for the preparation of sterile injections, the preparation method is vacuum drying and freeze drying to produce a powder of the active ingredient and any additional required ingredients from a previously sterile filtered solution thereof.
[0200] Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be placed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be mixed with an excipient and used in the form of tablets, lozenges or capsules. Oral compositions can also be prepared using a liquid carrier as a mouthwash, wherein the compound in the liquid carrier is orally administered and gargled, coughed or swallowed. Pharmaceutically compatible binders and / or excipients may be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar nature: binders (e.g., microcrystalline cellulose, tragacanth gum or gelatin); excipients (e.g., starch or lactose), disintegrants (e.g., alginic acid, Primogel or corn starch); lubricants (e.g., magnesium stearate or sterol esters); glidants (e.g., colloidal silicon dioxide); sweeteners (e.g., sucrose or saccharin); or flavorings (e.g., mint, methyl salicylate or orange flavoring).
[0201] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.
[0202] Administration may also be systemic via transmucosal or transdermal administration. For transmucosal or transdermal administration, penetrants suitable for the permeation barrier are used in the formulation. Such penetrants are well known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration may be achieved using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels, or creams commonly known in the art.
[0203] The active compound can be prepared with a pharmaceutically acceptable carrier (e.g., a controlled release formulation, including implants and microencapsulated delivery systems) that will protect the compound from rapid elimination from the body. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such preparations are obvious to those skilled in the art. These materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes that target monoclonal antibodies to viral antigens to infected cells) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, such as described in U.S. Pat. No. 4,522,811. It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. The dosage unit form used herein refers to physically discrete units suitable as single doses for subjects to be treated; each unit contains a predetermined amount of active compound, which is calculated to produce the desired therapeutic effect in combination with the desired pharmaceutical carrier. The specification for the dosage unit form employed is dictated by and directly depends on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
[0204] In therapeutic applications, the dosage of the pharmaceutical composition used according to the application varies according to the medicament, the age, weight and clinical condition of the patient receiving treatment, the experience and judgment of the clinician or practitioner providing treatment, and other factors affecting the selected dosage. In general, the dosage should be sufficient to cause tumor growth to slow, and preferably to cause tumor growth to regress, and also preferably to cause complete regression of the cancer. The dosage range is from about 0.01 mg / kg / day to about 5000 mg / kg / day. The effective amount of the pharmaceutical preparation refers to the amount of objectively identifiable improvement indicated by a clinician or other qualified observer. For example, the regression of a patient's tumor can be measured with reference to the diameter of the tumor. The reduction in tumor diameter indicates regression. After treatment stops, the failure of the tumor to recur also indicates regression. As used herein, the term "dosage effective manner" refers to the amount of an active compound that produces a desired biological effect in a subject or cell.
[0205] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
[0206] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.
[0207] The compounds of the present application can also be prepared into esters, for example, pharmaceutically acceptable esters. For example, the carboxylic acid functional group in the compound can be converted into its corresponding ester, such as methyl ester, ethyl ester or other ester. In addition, the alcohol group in the compound can be converted into its corresponding ester, such as acetate, propionate or other ester.
[0208] The compound or its pharmaceutically acceptable salt is administered orally, nasally, transdermally, pulmonary, by inhalation, orally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compound or its pharmaceutically acceptable salt is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.
[0209] The dosage regimen for using the compound is selected based on a variety of factors, including the type, race, age, weight, sex and physical condition of the patient; the severity of the disease to be treated; the route of administration; the patient's renal and liver function; and the specific compound used or its pharmaceutically acceptable salt, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative. An ordinary skilled physician or veterinarian can easily determine and prescribe the effective amount of drug required to prevent, counter or stop the progression of the disease.
[0210] The preparation and administration techniques of the compounds disclosed in this application can be found in Remington: the Science and Practice of Pharmacy, 19 th edition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical preparation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compound or its pharmaceutically acceptable salt will be present in the pharmaceutical composition in an amount sufficient to provide the desired dosage within the range described herein.
[0211] Unless otherwise indicated, all percentages and ratios used herein are by weight. Other features and advantages of the present application will be apparent from the different embodiments. The provided embodiments illustrate different compositions and methods useful in practicing the present application. The embodiments do not limit the claimed application. Based on the present application, those skilled in the art can identify and use other compositions and methods useful in practicing the present application.
[0212] Example
[0213] The application is further described by the following examples and synthesis schemes, and these examples and synthesis schemes should not be construed as limiting the scope or spirit of the application to specific procedures described herein. It should be understood that providing examples is to illustrate certain embodiments and is not meant to limit the scope of the application. It should also be understood that, without departing from the spirit of the application and / or the scope of the appended claims, various other embodiments, modifications and equivalents thereof that can be imagined by those skilled in the art can be adopted.
[0214] Study on the combination of compound of formula I and venetoclax
[0215] A study of primary CLL cells showed that the viability of cells treated with venetoclax was significantly reduced compared with vehicle (p < 0.0001); the addition of ibrutinib or nemtabrutinib increased cytotoxicity by 6% and 10%, respectively, compared with venetoclax alone ( Figure 1A Primary CLL cells were treated with DMSO, venetoclax (5 nM), nemtarutinib (1 μM), ibrutinib (1 μM), or their combination. Ibrutinib was washed off after 1 h, and the total incubation time was 24 h. Cell viability was assessed by flow cytometry after Annexin V / PI staining. Data were normalized to the DMSO control group. Raw data were analyzed using a linear mixed-effects model, and p values were adjusted for multiple comparisons using the Tukey method (*, p≤0.05, **, p≤0.01, ***, p≤0.001).
[0216] Figure 1B The effects of venetoclax and BTKi combinations on BCR signaling are shown. Primary CLL cells were treated with DMSO, venetoclax (5nM), nemtarutinib (1μM), ibrutinib (1μM), or their combination. Ibrutinib was washed off after 1 hour, and the total incubation time was 24 hours. Cells were stimulated with 10μg of plate-bound anti-IgM for 15 minutes before whole cell lysates were collected and analyzed using SDS-PAGE.
[0217] for Figures 1C to 1E All immunoblots of primary CLL patient samples were quantified using densitometry software (AlphaView). Protein levels were normalized to the GAPDH loading control ( Figure 1C :pBTK, Figure 1D :pERK, Figure 1E:MCL-1) are reported as fold changes relative to vehicle control. Raw data normalized to GAPDH loading control were analyzed using a linear mixed effects model and p values were adjusted for multiple comparisons using Tukey's method (*, p≤0.05, **, p≤0.01, ***, p≤0.001).
[0218] Both ibrutinib and nemtarutinib significantly inhibited BTK Y223 14.4% (ibrutinib vs. vehicle p = 0.0021, nemtarutinib vs. vehicle p = 0.0024) and was not affected by the addition of venetoclax ( Figure 1C ). Nemtarutinib inhibited ERK phosphorylation to a greater extent than ibrutinib (nemtarutinib vs. stimulation vehicle p<0.0001, nemtarutinib vs. ibrutinib p=0.0461), and this inhibitory effect was not affected by the addition of venetoclax ( Figure 1D ). However, the combination of BTKi+venetoclax significantly reduced the expression of the BCL2 family protein MCL1 (ibrutinib combination vs. stimulation vehicle p=0.0001, nemtabrutinib combination vs. stimulation vehicle p=0.0003). In addition, ibrutinib+venetoclax significantly reduced the expression of MCL-1 compared with either drug alone (combination vs. ibrutinib p=0.0171, combination vs. venetoclax p=0.0262) ( Figure 1E ).
[0219] for Figure 1F Primary CLL cells from nemtabrutinib-treated patients were co-cultured with NK Tert stromal cells prior to BH3 profiling using BIM, BAD, MS-1, Y4ek, and PUMA2A peptides. Baseline cytochrome c release measured in DMSO-treated cells was subtracted from all conditions tested and controls provided. Cytochrome c was released in response to interaction with BIM, BAD, and Y4ek peptides, indicating that the cells were dependent on BCL-2 and BCL-xL. Raw data were analyzed using linear mixed effects models, and p values were adjusted for multiple comparisons using Tukey's method. All statistics were compared to DMSO-treated controls (*, p≤0.05, **, p≤0.01, ***, p≤0.001). BH3 profiling of samples from 3 patients treated with nemtabrutinib showed cytochrome c released in response to interaction with BIM, BAD, and Y4ek, indicating that these CLL cells remained dependent on BCL2 and BCL-xL ( Figure 1F)(Ryan J, et al., Biol Chem. 2016; 397(7):671-8). This indicates sensitivity to venetoclax.
[0220] The in vivo efficacy of venetoclax combined with ibrutinib or nemtabrutinib was tested using the Eμ-TCL1 adoptive transfer CLL mouse model (Bichi R, et al. Proc Natl Acad Sci US A. 2002; 99(10): 6955-60). Figure 2A Methods: Splenocytes from Eμ-TCL1 donor mice were implanted into 93 C57BL / 6NTac mice by tail vein injection. Recipient mice were randomized into treatment groups after development of CD5+CD19+ disease as assessed by peripheral blood flow cytometry. Mice were treated daily by oral gavage with vehicle, venetoclax (100 mg / kg), nemtarutinib (75 mg / kg), ibrutinib (25 mg / kg), venetoclax (100 mg / kg) and nemtarutinib (75 mg / kg), or venetoclax (100 mg / kg) and ibrutinib (25 mg / kg). Due to the large scale of the study, splenocytes from multiple Eμ-TCL1 donors were required to engraft C57BL / 6NTac mice. Splenocytes from four donors were implanted into groups of 48, 25, 17, and 3 recipient mice, respectively.
[0221] Peripheral blood disease progression was monitored weekly by flow cytometry and reported as %CD45+ cellsCD5+CD19+( Figure 2B ). Higher variability was observed between subject groups, including a group of subjects without BCR-dependent disease (as evidenced by a lack of response to ibrutinib). These groups were excluded from the analysis. Survival differences were evaluated in 48 mice transplanted with spleen cells from a single donor with BCR-dependent disease. The median survival time of mice treated with ibrutinib was 56.5 days, while the median survival time of mice treated with ibrutinib and venetoclax was 66 days (ns, p=to be determined). The median survival time of mice treated with nemtarutinib was 81.5 days, while the median survival time of mice treated with nemtarutinib and venetoclax was 92 days (preliminary p=0.03). Mice treated with vehicle and venetoclax had similar overall survival times (median 31 days and 34.5 days, respectively). In addition, the combination of nemtabrutinib and venetoclax prolonged survival compared to the combination of ibrutinib and venetoclax (preliminary p=0.003).
[0222] Figure 2CKaplan Meier estimated survival of mice with BCR-dependent disease treated with BTKi, venetoclax, or the combination is shown. Nemtarutinib's inhibitory effect on BCR signaling was not affected by the addition of venetoclax, while venetoclax's cytotoxicity was not affected by the addition of nemtarutinib. In vivo data showed that treatment with the combination of nemtabrutinib and venetoclax was superior to treatment with either drug alone.
[0223] Additional studies of nemtrutinib + venetoclax versus venetoclax + rituximab
[0224] Purpose and End Point
[0225] In patients 18 years of age or older with relapsed or refractory CLL / SLL who have failed at least one prior therapy:
[0226]
[0227]
[0228] Part 1 (Dose Escalation and Confirmation) Design
[0229] Part 1 consists of an open-label, non-randomized, dose-escalation and confirmatory design to confirm the optimal dose of nemtabrutinib in combination with venetoclax. Part 1 will have a maximum of approximately 30 participants, 15 participants per dose level. Two pre-specified dose levels of nemtabrutinib will be evaluated in combination with venetoclax:
[0230] Dose 1: 45 mg (starting dose level)
[0231] Dose 2: 65 mg
[0232] The end of the dose-limiting toxicity (DLT) assessment window will correspond to approximately 12 weeks after participants receive the first dose of nemtabrutinib.
[0233] Part 2 Design
[0234] Part 2 was a randomized, active-controlled, parallel-group, multisite, open-label study of nemtabrutinib plus venetoclax in participants with relapsed / refractory CLL / SLL.
[0235] Approximately 690 eligible participants will be enrolled in the study and randomized into 1 of the following 2 groups:
[0236] Treatment group: nemtarutinib + venetoclax
[0237] Control group: venetoclax + rituximab (VR) (or rituximab biosimilar)
[0238] In the treatment group, nemtabrutinib was continued for up to 2 years. Venetoclax was increased over 4 weeks to a dose of 400 mg. In the control group, venetoclax was increased over 4 weeks to a dose of 400 mg. Rituximab was started at 375 mg / m 2 The dose was subsequently increased to 500 mg / m 2 .
[0239] PFS was the primary endpoint of Part 2 and was defined as the time from randomization to the first documented disease progression or death from any cause, whichever occurred first, as assessed by 2018iwCLL criteria by BICR (blinded independent central review).
[0240] Secondary endpoints included undetectable MRD in the bone marrow at month 14 as assessed by central laboratory, OS, OR, DOR, and safety. Exploratory efficacy endpoints included OR, and response categories included PRL.
[0241] Study treatment will continue for 2 years or until unacceptable toxicity, confirmed disease progression (imaging or non-imaging progression), or other discontinuation criteria are reached. Part 2 will evaluate:
[0242] a. According to BICR assessment, based on the 2018iwCLL criteria, nemtarutinib + venetoclax is superior to VR in terms of PFS.
[0243] b. Nemtarutinib plus venetoclax was superior to VR in terms of the incidence of undetectable MRD in the bone marrow at month 14, as assessed by the central laboratory
[0244] c. In terms of OS, nemtarutinib + venetoclax is superior to VR
[0245] d. Scientific evidence that nemtarutinib + venetoclax is superior to VR in terms of ORR according to the 2018iwCLL criteria as assessed by BICR
[0246] This is a randomized, active-controlled, parallel-group, open-label, phase 3 study designed to evaluate nemtabrutinib (a reversible, noncovalent, ATP-competitive inhibitor of BTK) plus venetoclax compared with VR in participants with CLL / SLL who are relapsed or refractory after at least 1 prior therapy.
[0247] treat
[0248] Treatment Group (nemtarutinib + venetoclax; Part 1 and Part 2)
[0249] Venetoclax was administered at doses of 20 to 400 mg daily during a 5-week ramp-up phase, followed by 400 mg daily after the ramp-up phase. Venetoclax was continued until confirmed disease progression, unacceptable toxicity, meeting discontinuation criteria, or 2 years.
[0250] Nemtabrutinib was administered orally daily at a dose of 45 mg or 65 mg at least 10 hours after venetoclax administration. Each cycle consisted of 4 weeks (28 days).
[0251] Control group (venetoclax + rituximab; part 2)
[0252] Venetoclax was administered at doses of 20 to 400 mg daily during a 5-week ramp-up phase, followed by 400 mg daily after the ramp-up phase. Venetoclax was continued until confirmed disease progression, unacceptable toxicity, meeting discontinuation criteria, or 2 years.
[0253] Rituximab (or rituximab biosimilar) is administered as an IV infusion. The initial dose is 375 mg / m 2 , followed by 500 mg / m 2 , for subsequent infusion.
[0254] Time of administration
[0255] Vinakara
[0256] Participants will be instructed to take the tablets orally QD in the morning with food and water. Venetoclax will be administered in increasing doses over 5 weeks.
[0257] Nemtabrutinib
[0258] Subjects enrolled in Part 1 or randomized to a treatment group in Part 2 will be instructed to take the tablet orally QD under fasting conditions (1 hour before or 2 hours after a meal), preferably at the same time each day. Administer nemtabrutinib at least 10 hours after venetoclax.
[0259] Participants will be instructed to take the assigned dose of nemtabrutinib unless that dose is reduced for management of an AE. Treatment will continue until unacceptable toxicity, documented disease progression, or other discontinuation criteria are reached.
[0260] Rituximab
[0261] Rituximab (or rituximab biosimilar) will be administered clinically.
[0262] First infusion: Start at 50 mg / hour. In the absence of infusion toxicity, increase the infusion rate by 50 mg / hour every 30 minutes to a maximum of 400 mg / hour.
[0263] Subsequent infusions (standard infusions): Start at 100 mg / hour. In the absence of infusion toxicity, increase the infusion rate by 100 mg / hour every 30 minutes to a maximum of 400 mg / hour.
[0264] Table 1 below shows the details of the groups / interventions in this study:
[0265] Table 1
[0266]
[0267]
[0268] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed within the scope of the following claims.
Claims
1. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof for treating a BTK-mediated disease or condition.
2. The pharmaceutical composition of claim 1, wherein the second agent is selected from venetoclax, BI-97C1, sabutoclax, navitoclax, obaclax, 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylthiobutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide (ABT-737), N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide (TW-37), APG-1252, APG-2575 or S55746.
3. The pharmaceutical composition of claim 2, wherein the second agent is venetoclax.
4. A method of treating a BTK-mediated disorder in a subject in need thereof, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof.
5. The method of claim 4, wherein a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered to a patient in need thereof after administration of a therapeutically effective amount of at least one second agent or a pharmaceutically acceptable salt thereof.
6. The method for treating a BTK-mediated disorder according to claim 4 or 5, wherein the BTK-mediated disorder is a cancer selected from CLL, SLL or MLL.
7. The method of claim 6, wherein the at least one second agent is selected from a BCL-2 inhibitor selected from venetoclax, BI-97C1, sabutoclax, navitoclax, obaclax, 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylthiobutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide (ABT-737), N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide (TW-37), APG-1252, APG-2575 or S55746.
8. The method of claim 7, wherein the at least one second agent is venetoclax.
9. The method of claim 7, wherein about 30 to about 80 mg of the compound of formula (I) is administered.
10. The method of claim 9, wherein about 45 mg of the compound of formula (I) is administered.
11. The method of claim 9, wherein about 65 mg of the compound of formula (I) is administered.
12. The method of claim 9, wherein about 80 mg of the compound of formula (I) is administered.
13. The method of claim 8, wherein about 20 to about 400 mg of venetoclax is administered.
14. The method of claim 8, wherein about 20 to about 400 mg of venetoclax is administered.
15. A method of treating cancer comprising co-administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of venetoclax or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from CLL, SLL or MLL, and after administering about 20 to about 400 mg of venetoclax or a pharmaceutically acceptable salt thereof, about 30 mg to about 80 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered.
16. The method of claim 15, wherein 65 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered.
17. The method of claim 15, wherein 400 mg of venetoclax or a pharmaceutically acceptable salt thereof is administered.
Citation Information
Patent Citations
Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20050176701A1
Human Anti-PD-1, PD-l1, and PD-l2 antibodies and uses therefor
US20110271358A1
Inhibition of B7-H1 / CD80 interaction and uses thereof
US20110280877A1
Targeted Binding Agents Against B7-H1
US20130034559A1
Methods of using Anti-PD-l1 antibodies and their use to enhance t-cell function to treat tumor immunity
US20130045201A1
Cited By
Application of CVT-313 in preparation of medicine for resisting monkey pox virus
CN122124058A
